var title_f4_44_4800="Pereira stitch";
var content_f4_44_4800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Pereira stitch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pereira described a technique in which a series of transverse and longitudinal sutures of a delayed absorbable multifilament suture are placed around the uterus via a series of bites into the submucosal myometrium. Two or three rows of these sutures are placed in each direction to completely envelope and compress the uterus, similar to the way one might truss a stuffed roast. When the transverse sutures are brought through the broad ligament, care should be taken to avoid damaging blood vessels, ureters, and fallopian tubes. The longitudinal sutures begin and end at the last transverse suture nearest the cervix, and do not enter the uterine cavity. The myometrium should be manually compressed prior to tying down the sutures to facilitate maximal compression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Pereira, A, Nunes, F, Pedroso, S, et al. Compressive uterine sutures to treat postpartum bleeding secondary to uterine atony. Obstet Gynecol 2005; 106:569.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4800=[""].join("\n");
var outline_f4_44_4800=null;
var title_f4_44_4801="Nilvadipine: International drug information";
var content_f4_44_4801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nilvadipine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arcadipin (AT);",
"     </li>",
"     <li>",
"      Escor (AT, DE, DK, FI, LU);",
"     </li>",
"     <li>",
"      Nivadil (CH, DE, JP);",
"     </li>",
"     <li>",
"      Tensan (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F4089349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Nivadipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4089350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4089352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Hypertension: 4-16 mg/day; reduce dosage to a maximum dose of 8 mg in patients with cirrhosis or with concomitant use with cimetidine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Cerebrovascular disease: 2-4 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Angina pectoris: 8-16 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10513 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4801=[""].join("\n");
var outline_f4_44_4801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369876\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089349\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089350\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089352\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821064\">",
"      Product Availability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10513\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10513|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_44_4802="Laparoscopic oophorectomy";
var content_f4_44_4802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic oophorectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two to three loops are placed around the ovary and cinched down across the ovarian vessels and the utero-ovarian ligament. The ovary is then excised distal to the last loop.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4802=[""].join("\n");
var outline_f4_44_4802=null;
var title_f4_44_4803="Patient information: Urethritis (The Basics)";
var content_f4_44_4803=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83668\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21906\">",
"         Patient information: Genital herpes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/13/16594\">",
"         Patient information: Genital warts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1940\">",
"         Patient information: Screening for sexually transmitted diseases (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/61/10195\">",
"         Patient information: Syphilis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8162\">",
"         Patient information: Trichomoniasis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/47/20210\">",
"         Patient information: Urinary tract infections in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/2/22563\">",
"         Patient information: Barrier methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/14/24802\">",
"         Patient information: Chlamydia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/3/36916\">",
"         Patient information: Genital herpes (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/60/4035\">",
"         Patient information: Genital warts in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1730\">",
"         Patient information: Gonorrhea (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/45/38610\">",
"         Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/0/7170\">",
"         Patient information: Symptoms of HIV infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/18/32036\">",
"         Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Urethritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/urethritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H539583107\">",
"      <span class=\"h1\">",
"       What is urethritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The urethra is the tube that carries urine from the bladder to the outside of the body (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). Urethritis is the medical term for when the urethra gets irritated or inflamed.",
"     </p>",
"     <p>",
"      People who have urethritis can have pain, burning, or stinging when they urinate. They also sometimes have discharge, meaning they leak fluid from the penis or vagina. Men with urethritis can have redness or swelling at the tip of the penis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539583139\">",
"      <span class=\"h1\">",
"       What causes urethritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Urethritis is usually caused by an infection. The most common cause is a sexually transmitted disease. Sexually transmitted diseases, often called STDs, are infections you can catch during sex.",
"     </p>",
"     <p>",
"      STDs that can cause urethritis include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chlamydia",
"       </li>",
"       <li>",
"        Gonorrhea",
"       </li>",
"       <li>",
"        Trichomoniasis",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539583154\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have symptoms of urethritis, see a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539583169\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. The doctor or nurse will probably need to take a urine sample or a sample of fluid from your vagina (if you are woman) or your penis (if you are a man). It&rsquo;s also possible you will have a blood test. These tests can show if you have an infection and what kind.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539583184\">",
"      <span class=\"h1\">",
"       How is urethritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment usually involves taking antibiotics.",
"     </p>",
"     <p>",
"      If you are treated for an STD, you should not have sex with anyone until 7 days after you start antibiotics and until you have no more symptoms.",
"     </p>",
"     <p>",
"      If you learn that you have an STD, you should tell all the people you have had sex with recently. They might also be infected (even if they have no symptoms) and need treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539583199\">",
"      <span class=\"h1\">",
"       Can urethritis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Since urethritis is usually caused by an STD, you can reduce your chances of getting urethritis again by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using a latex condom every time you have sex",
"       </li>",
"       <li>",
"        Avoiding sex when you or your partner has any symptoms that could be caused by an infection (such as itching, discharge, or pain with urination)",
"       </li>",
"       <li>",
"        Not having sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you had an STD at any time, your doctor or nurse might also check you for other STDs now or in the future. People can get more than 1 STD at the same time. Plus, STDs do not always cause symptoms, so it helps to check.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539583214\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"       Patient information: Screening for sexually transmitted diseases (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=see_link\">",
"       Patient information: Trichomoniasis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       Patient information: Genital warts (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       Patient information: Genital herpes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=see_link\">",
"       Patient information: Syphilis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20210?source=see_link\">",
"       Patient information: Urinary tract infections in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       Patient information: Chlamydia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       Patient information: Gonorrhea (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"       Patient information: Genital warts in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=see_link\">",
"       Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"       Patient information: Genital herpes (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=see_link\">",
"       Patient information: Symptoms of HIV infection (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"       Patient information: Barrier methods of birth control (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"       Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/44/4803?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83668 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4803=[""].join("\n");
var outline_f4_44_4803=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539583107\">",
"      What is urethritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539583139\">",
"      What causes urethritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539583154\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539583169\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539583184\">",
"      How is urethritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539583199\">",
"      Can urethritis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539583214\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=related_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=related_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=related_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=related_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=related_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=related_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=related_link\">",
"      Patient information: Trichomoniasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=related_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20210?source=related_link\">",
"      Patient information: Urinary tract infections in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_44_4804="Acute eosinophilic myocarditis";
var content_f4_44_4804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute eosinophilic myocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eosinophilic infilitration of the myocardium in a case of acute eosinophilic myocarditis in a 23-year old woman who went to transplant for a rapidly progressive dilated cardiomyopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Bilinska ZT, Bilinska M, Grzybowski J, et al. Unexpected eosinophilic myocarditis in a young woman with rapidly progressive dilated cardiomyopathy. Int J Cardiol 2002; 86:295. Copyright &copy;2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4804=[""].join("\n");
var outline_f4_44_4804=null;
var title_f4_44_4805="Tobramycin and dexamethasone: Patient drug information";
var content_f4_44_4805=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tobramycin and dexamethasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/50/38691?source=see_link\">",
"     see \"Tobramycin and dexamethasone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TobraDex&reg;;",
"     </li>",
"     <li>",
"      TobraDex&reg; ST",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tobradex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tobramycin, dexamethasone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Herpes, TB (tuberculosis), or yeast infection of the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wear contact lenses at any time while using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wear contact lenses at any time while using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11099 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4805=[""].join("\n");
var outline_f4_44_4805=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228654\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228655\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014029\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014028\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014033\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014034\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014036\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014031\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014032\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014037\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014038\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/50/38691?source=related_link\">",
"      Tobramycin and dexamethasone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_44_4806="Early cirrhosis in a 52-year-old";
var content_f4_44_4806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early cirrhosis in a 52-year-old woman with non A non B hepatitis (more likely chronic hepatitis C) low power, Masson trichrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is bridging fibrosis of portal triads, early nodule formation and interface hepatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4806=[""].join("\n");
var outline_f4_44_4806=null;
var title_f4_44_4807="Urinary tract infection in autosomal dominant polycystic kidney disease";
var content_f4_44_4807=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urinary tract infection in autosomal dominant polycystic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4807/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4807/contributors\">",
"     Arlene B Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4807/contributors\">",
"     Frederic F Rahbari-Oskoui, MD, MSCR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4807/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4807/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4807/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4807/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4807/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/44/4807/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 to 50 percent of patients with autosomal dominant polycystic kidney disease (ADPKD) will have a urinary tract infection during their lifetime. Cyst infections responsible for hospitalization occur much less frequently, approximately 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/1\">",
"     1",
"    </a>",
"    ]. An infected cyst and acute pyelonephritis are the most common kidney infections, although complications such as a perinephric abscess and bacteremia can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Cyst infection incidence rates are approximately 0.01 episode per patient per year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/1\">",
"     1",
"    </a>",
"    ]. Even nonfunctional end-stage polycystic kidneys may be a source of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/4\">",
"     4",
"    </a>",
"    ]. After transplantation, special attention needs to be paid to the native kidneys in patients who present with sepsis, fever, flank or abdominal tenderness.",
"   </p>",
"   <p>",
"    By convention, UTI is defined either as a lower tract (acute cystitis) or upper tract (acute pyelonephritis) infection. This topic will review issues related to UTIs, particularly upper tract infections, in patients with ADPKD. Discussions related to UTI in patients without ADPKD as well as the therapy of ADPKD and other renal manifestations of ADPKD can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link&amp;anchor=H2922196#H2922196\">",
"     \"Acute complicated cystitis and pyelonephritis\", section on 'Pyelonephritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCE OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with UTIs in the general population, UTIs in patients with ADPKD are more likely to occur in women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. The infections are typically caused by Gram negative enteric organisms.",
"   </p>",
"   <p>",
"    With respect to upper tract infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram negative enteric organism ascend from the bladder among patients with pyelonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2,5-7\">",
"       2,5-7",
"      </a>",
"      ]. Such infections may be associated with dysuria and frequency due to bladder infection.",
"     </li>",
"     <li>",
"      In cyst infection, the source of the organisms is also often a gram negative enteric organism with E coli accounting for approximately 75 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/1\">",
"       1",
"      </a>",
"      ]. However the causes of cyst infection are often more difficult to document since the cysts may not be in communication with the collecting system, and the urine culture is often negative. Support for hematogenous spread has been documented in a case report in which Staphylococcus aureus bacteremia with cyst fluid cultures positive for the same organism and negative urine cultures were identified in an ADPKD patient with a history of intravenous drug use [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16102?source=see_link\">",
"       \"Bacterial adherence and other virulence factors for urinary tract infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urinary tract instrumentation can also be a source of infection and should be avoided whenever possible. In addition, approximately 20 percent of patients with ADPKD develop nephrolithiasis, and stones may be a source of recurrent infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Nephrolithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of a kidney infection in ADPKD include fever and flank pain, and usually nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/9\">",
"     9",
"    </a>",
"    ]. These infections may be due either to renal parenchymal infection (acute pyelonephritis) or an infected cyst, and distinguishing between them is often difficult.",
"   </p>",
"   <p>",
"    With pyelonephritis, the manifestations may be more acute, with features similar to any patient without ADPKD. By comparison, patients with a cyst infection frequently have a more insidious presentation, and may have a specific area of tenderness that relates to the location of the cyst infection. Importantly, both pyelonephritis and cyst infection may be present simultaneously in an ADPKD patient.",
"   </p>",
"   <p>",
"    After renal transplantation, ADPKD patients are at higher risk for native kidney infections compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/4\">",
"     4",
"    </a>",
"    ]. The classical signs and symptoms of native kidney cyst infection or pyelonephritis (fever, pain, dysuria) can be minimal or absent in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/4,10\">",
"     4,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a kidney infection in a patient with ADPKD requires a similar approach as in a patient without ADPKD, and includes a thorough physical examination, urinalysis, urine Gram stain, urine culture with antimicrobial susceptibility testing, and in most cases, a blood culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link&amp;anchor=H899949177#H899949177\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination and urinary findings are not specific, but certain characteristics may help determine whether the patient has pyelonephritis or a cyst infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an infected cyst may have a new area of discrete tenderness on physical examination, whereas pyelonephritis tends to be associated with diffuse flank pain.",
"     </li>",
"     <li>",
"      The presence of white cell casts is suggestive of acute pyelonephritis, and the urine culture is typically positive. In contrast, the sediment may be bland and the urine culture may be negative in patients with an infected cyst, since cysts may not be in contact with the renal collecting system [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2,5,6\">",
"       2,5,6",
"      </a>",
"      ]. Blood cultures may be positive in both pyelonephritis and cyst infections [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pyuria is found in up to 45 percent of uninfected patients with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, pyuria without an appropriate clinical picture cannot be used to diagnose UTI.",
"   </p>",
"   <p>",
"    Traditional radiologic studies (including ultrasound, CT-scan, MRI) are generally of little help in the initial evaluation, since the cyst changes induced by an infection are similar to those with cyst hemorrhage; thus, many uninfected cysts appear abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2\">",
"     2",
"    </a>",
"    ]. However, gallium or indium scanning localizes only inflammation and is positive in about one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, 18F-fluorodeoxyglucose",
"    <span class=\"nowrap\">",
"     (FDG)-PET/CTPET",
"    </span>",
"    scan identified renal and hepatic cyst infections and differentiated between kidney and liver in limited case series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evaluation will depend upon the response to initial therapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Antimicrobial therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal distinction to be made in a patient with ADPKD presenting with flank pain is between a kidney infection, cyst infection, and cyst hemorrhage. Since the symptoms are similar, distinguishing between these disorders is difficult without a positive urine culture. Flank pain in the absence of fever is more likely to result from bleeding into and gradual enlargement of a cyst. However, cyst hemorrhage can be associated with transient fever and leukocytosis. In this setting, findings suggestive of hemorrhage rather than infection are the abrupt onset of pain and the absence of antecedent dysuria and frequency.",
"   </p>",
"   <p>",
"    Nephrolithiasis (including staghorn calculi) may also be a source of flank pain in patients with ADPKD as well as a source of UTIs. Imaging studies will identify the presence of kidney stones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a suspected kidney infection and relatively marked systemic symptoms are typically hospitalized and, when necessary, empirically begun on parenteral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. As previously mentioned, although certain characteristics may help determine whether the patient has pyelonephritis or a cyst infection, it is frequently difficult to initially distinguish between the two.",
"   </p>",
"   <p>",
"    Thus, a major issue surrounding the choice of initial empiric therapy is whether the antibiotic is able to successfully treat both types of infection. Since cysts larger than 2 cm in diameter are not in communication with a filtering glomerulus, the antimicrobial must enter the cyst by a mechanism other than glomerular filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/14\">",
"     14",
"    </a>",
"    ]. The major mechanism is diffusion, which is more pronounced with lipid-soluble drugs.",
"   </p>",
"   <p>",
"    Drugs that both achieve therapeutic concentrations within the cysts and are active against Gram negative enteric organisms include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (and other fluoroquinolones),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2,8,15-20\">",
"     2,8,15-20",
"    </a>",
"    ]. On the other hand, aminoglycosides and the penicillins frequently do not penetrate cysts and are not predictably effective treatment for infected cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2,5,9\">",
"     2,5,9",
"    </a>",
"    ]. The ability of newer antibiotics used against resistant organisms (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ) to penetrate cysts has not been examined.",
"   </p>",
"   <p>",
"    We most commonly treat initially with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (or another intravenous fluoroquinolone). This choice is based upon the rationale that fluoroquinolones penetrate renal cysts and are also recommended parenteral agents for the initial empiric therapy of acute complicated pyelonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link&amp;anchor=H2922196#H2922196\">",
"     \"Acute complicated cystitis and pyelonephritis\", section on 'Pyelonephritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some centers, however, a fluoroquinolone is not used for initial empiric therapy since quinolone resistance is an increasing problem. In this setting, empiric therapy is initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We make antibiotic adjustments based upon results of the urine culture, which is usually available within 48 hours.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    should be substituted if the patient has a streptococcal or staphylococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    is also a good alternative for resistant group A streptococcal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    should be used if anaerobic organisms are recovered.",
"   </p>",
"   <p>",
"    The patient should respond rapidly if the appropriate intravenous antimicrobial is administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link&amp;anchor=H2922196#H2922196\">",
"     \"Acute complicated cystitis and pyelonephritis\", section on 'Pyelonephritis'",
"    </a>",
"    .) Patients with an infected cyst presenting with only mild or local symptoms can be treated primarily with oral therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    or a fluoroquinolone, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In those who do not respond to antibiotic therapy with improvement in symptoms within 72 hours or have continued fevers for more than one week, one of the following may be present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Untreated microorganisms are playing a pathogenic role",
"     </li>",
"     <li>",
"      Stone or obstruction of the urinary tract will not permit successful treatment",
"     </li>",
"     <li>",
"      The infected cyst is too large to respond to parenteral antibiotics",
"     </li>",
"     <li>",
"      Other causes of fever are present, including drug-related fevers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this setting, we suggest renal imaging. We prefer a spiral CT scan to help determine the size of a possible infected cysts, and to detect a stone or urinary tract obstruction. In situations of non-response to therapy or a deteriorating clinical condition, diagnostic information may be derived via percutaneous drainage of the suspicious cyst for documentation of the infecting organisms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drainage of the abscess cavity.",
"   </p>",
"   <p>",
"    The duration of therapy will depend upon response and the presence of pyelonephritis or an infected cyst:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with acute pyelonephritis (and no evidence of infected cyst or abscess), we continue with an oral antibiotic based upon the results of the urine culture for a total course of therapy of a minimum of 10 to 14 days.",
"     </li>",
"     <li>",
"      The optimal duration of therapy for infected cysts is unclear. Patients with a presumed cyst infection are usually treated for at least four weeks, and sometimes for up to six weeks. If the infection recurs after withdrawal of antimicrobials, therapy may have to be reinstituted and continued for two to three months or longer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/6\">",
"       6",
"      </a>",
"      ]. In cases of an extremely large cyst infection, antibiotic therapy alone may not be sufficient to successfully treat the infection, and cyst drainage may be indicated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other interventions'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A perinephric abscess may also be present if the patient shows little or an incomplete response to antibiotic therapy within five to seven days. This infection may require treatment with two parenteral agents active against the infecting organism, which is given for two to three weeks or sometimes longer. The management of perinephric abscesses is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"     \"Renal and perinephric abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gas forming organisms resulting in an emphysematous cyst is a rare complication of renal cyst infections in ADPKD. However, when present, a high mortality rate is associated and urgent nephrectomy should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients will eventually respond to the administration of appropriate antimicrobials. Large infected cysts (greater than three to five centimeters in diameter) are more likely to fail medical therapy and therefore to require other interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous or surgical drainage of the cyst is both infrequently necessary and hard to perform, since it is usually difficult to ascertain radiologically which of the many cysts is infected. Case reports and a limited case series of percutaneous drainage of infected cysts have demonstrated a high success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. However, a prospective randomized study comparing medical and interventional therapy has not been performed.",
"   </p>",
"   <p>",
"    In contrast to the limited role of cyst drainage for cyst infection, drainage may be indicated for a perinephric abscess, which is diagnosed by ultrasonography or CT scan, particularly if the abscess is larger than 3 cm in diameter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"     \"Renal and perinephric abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stone removal procedures may be required if nephrolithiasis is contributing to recurrent UTIs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=see_link\">",
"     \"Management of struvite or staghorn calculi\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical nephrectomy is the treatment of last resort, because of potential complications and the potential adverse effects of removing a partially functioning kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there are a few settings in which nephrectomy is sometimes considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients infected with gas forming organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with recurrent, recent or refractory infections who are about to undergo renal transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/23\">",
"       23",
"      </a>",
"      ]. In this setting, nephrectomy will minimize the risk of post-transplant infection when immunosuppressive agents are administered to prevent rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/2\">",
"       2",
"      </a>",
"      ]. In the absence of recurrent infections, however, post-transplant rates of UTI are comparable between nephrectomized and non-nephrectomized PKD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4807/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a staghorn calculus causing recurrent UTIs in a relatively nonfunctioning kidney. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=see_link\">",
"       \"Management of struvite or staghorn calculi\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 30 to 50 percent of patients with autosomal dominant polycystic kidney disease (ADPKD) will have one or more kidney infections during their lifetime. As in UTI in patients without ADPKD, it is typically caused by gram negative enteric organisms which ascend from the bladder. Vesicoureteral reflux, nephrolithiasis, and urinary tract instrumentation can be contributory.",
"     </li>",
"     <li>",
"      Infected cysts and acute pyelonephritis are the most common causes of upper UTI in ADPKD. In each of these, flank pain and fever are typically present. Acute pyelonephritis is suggested by the presence of white cell casts, whereas an infected cyst may present with a new area of discrete tenderness and a bland urine sediment. In addition, both parenchymal and cyst infection may be present in any given patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients suspected of having a kidney infection, a complete history and physical examination should be performed, and a urinalysis, urine culture with antimicrobial susceptibility testing, and blood cultures should be obtained. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemorrhage into a cyst and nephrolithiasis can also cause flank pain. Although fever can be present with cyst hemorrhage alone, they are not typically associated with pyuria or a positive urine or blood culture. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend initiating therapy of all patients with acute pyelonephritis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cyst infection who have marked systemic symptoms (eg, high fever, flank pain, nausea and vomiting) with intravenous antibiotics (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We propose the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For the therapy of either acute pyelonephritis or an infected cyst, we recommend initial treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (or other intravenous fluoroquinolone), unless fluoroquinolone resistance is an issue. This is based upon the rationale that fluoroquinolones penetrate renal cysts and are also recommended parenteral agents for the initial empiric therapy of acute complicated pyelonephritis. Therapy is modified based upon the urine culture. Intravenous therapy is discontinued once systemic symptoms resolve.",
"     </li>",
"     <li>",
"      In some centers where quinolone resistance is an increasing problem, empiric therapy may be initiated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients with acute pyelonephritis (and no evidence of infected cyst or abscess), we continue with an oral antibiotic based upon the results of the urine culture for a total course of therapy of a minimum of 10 to 14 days.",
"     </li>",
"     <li>",
"      For patients with infected cysts, we continue a fluoroquinolone orally for a minimum of four and up to six weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Antimicrobial therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the therapy of an infected cyst in patients with minimal or no systemic symptoms, we recommend therapy with an oral antibiotic that has demonstrated cyst penetration. Either a fluoroquinolone (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      are reasonable alternatives, but the local bacterial susceptibility patterns must be considered.",
"     </li>",
"     <li>",
"      In those who do not respond to antibiotic therapy with improvement in symptoms within 72 hours or have continued fevers for more than one week, we suggest performing a spiral CT scan without contrast to evaluate for the presence of stones or a perinephric abscess, and to establish the size of the infected cyst. If indicated, diagnostic information may also be derived via percutaneous drainage. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A perinephric abscess may require more prolonged therapy with intravenous antibiotics with activity against the likely organisms (typically Gram negative organisms). Drainage may be indicated, particularly if the abscess is larger than three centimeters in diameter. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"       \"Renal and perinephric abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Percutaneous or surgical drainage and nephrectomy are rarely necessary however cysts larger than 5 cm in diameter have been shown not to respond to long term parenteral antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of native kidney infections should be considered in renal transplant recipients with nonfunctional polycystic kidneys.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/1\">",
"      Sall&eacute;e M, Rafat C, Zahar JR, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/2\">",
"      Sklar AH, Caruana RJ, Lammers JE, Strauser GD. Renal infections in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1987; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/3\">",
"      Gibson P, Watson ML. Cyst infection in polycystic kidney disease: a clinical challenge. Nephrol Dial Transplant 1998; 13:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/4\">",
"      Stiasny B, Ziebell D, Graf S, et al. Clinical aspects of renal transplantation in polycystic kidney disease. Clin Nephrol 2002; 58:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/5\">",
"      Schwab SJ, Bander SJ, Klahr S. Renal infection in autosomal dominant polycystic kidney disease. Am J Med 1987; 82:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/6\">",
"      Gabow PA, Bennett WM. Renal manifestations: complication management and long-term outcome of autosomal dominant polycystic kidney disease. Semin Nephrol 1991; 11:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/7\">",
"      Milutinovic J, Fialkow PJ, Agodoa LY, et al. Autosomal dominant polycystic kidney disease: symptoms and clinical findings. Q J Med 1984; 53:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/8\">",
"      Chapman AB, Thickman D, Gabow PA. Percutaneous cyst puncture in the treatment of cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1990; 16:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/9\">",
"      Rizk D, Chapman AB. Cystic and inherited kidney diseases. Am J Kidney Dis 2003; 42:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/10\">",
"      Salehipour M, Jalaeian H, Salahi H, et al. Are large nonfunctional kidneys risk factors for posttransplantation urinary tract infection in patients with end-stage renal disease due to autosomal dominant polycystic kidney disease? Transplant Proc 2007; 39:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/11\">",
"      Bleeker-Rovers CP, de S&eacute;vaux RG, van Hamersvelt HW, et al. Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2003; 41:E18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/12\">",
"      Desouza RM, Prachalias A, Srinivasan P, et al. Differentiation between infection in kidney and liver cysts in autosomal dominant polycystic kidney disease: use of PET-CT in diagnosis and to guide management. Transplant Proc 2009; 41:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/13\">",
"      Migali G, Annet L, Lonneux M, Devuyst O. Renal cyst infection in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2008; 23:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/14\">",
"      Grantham JJ, Geiser JL, Evan AP. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int 1987; 31:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/15\">",
"      Bennett WM, Elzinga L, Pulliam JP, et al. Cyst fluid antibiotic concentrations in autosomal-dominant polycystic kidney disease. Am J Kidney Dis 1985; 6:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/16\">",
"      Elzinga LW, Golper TA, Rashad AL, et al. Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int 1987; 32:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/17\">",
"      Schwab SJ, Weaver ME. Penetration of trimethoprim and sulfamethoxazole into cysts in a patient with autosomal-dominant polycystic kidney disease. Am J Kidney Dis 1986; 7:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/18\">",
"      Elzinga LW, Golper TA, Rashad AL, et al. Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother 1988; 32:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/19\">",
"      Hiyama L, Tang A, Miller LG. Levofloxacin penetration into a renal cyst in a patient with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2006; 47:e9.",
"     </a>",
"    </li>",
"    <li>",
"     Hiyama, L, Tang, A, Miller, LG. Levofloxacin penetration into a renal cyst in a patient with autosomal dominant polycystic kidney disease. American Journal of Kidney Disease; 47(1):e9-e13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/21\">",
"      Van Zijl PS, Chai TC. Gas-forming infection from Clostridium perfringens in a renal cyst of a patient with autosomal dominant polycystic kidney disease. Urology 2004; 63:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/22\">",
"      Akinci D, Turkbey B, Yilmaz R, et al. Percutaneous treatment of pyocystis in patients with autosomal dominant polycystic kidney disease. Cardiovasc Intervent Radiol 2008; 31:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4807/abstract/23\">",
"      Rozanski J, Kozlowska I, Myslak M, et al. Pretransplant nephrectomy in patients with autosomal dominant polycystic kidney disease. Transplant Proc 2005; 37:666.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1676 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4807=[""].join("\n");
var outline_f4_44_4807=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCE OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16102?source=related_link\">",
"      Bacterial adherence and other virulence factors for urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=related_link\">",
"      Management of struvite or staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=related_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=related_link\">",
"      Renal and perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_44_4808="Polyhydramnios";
var content_f4_44_4808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Polyhydramnios",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4808/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4808/contributors\">",
"     Ron Beloosesky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4808/contributors\">",
"     Michael G Ross, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4808/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4808/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4808/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4808/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/44/4808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyhydramnios refers to excessive accumulation of amniotic fluid, which is associated with increased risks of adverse pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It is typically diagnosed by ultrasound examination and may be described qualitatively or quantitatively by various methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of polyhydramnios in a general obstetric population generally ranges from 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. Reported rates are influenced by variations in diagnostic criteria, the population studied (low or high risk), the threshold used (eg, mild, moderate, or severe), and the gestational age (preterm, term, or postterm). In one series of 93,332 singleton pregnancies delivering at a single hospital from 1991 to 1997, polyhydramnios was diagnosed during antepartum sonography in 708 pregnancies (0.7 percent of deliveries); mild, moderate, and severe disease occurred in 66, 22, and 12 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The integration of fluid flow into and out of the amniotic sac determines the ultimate volume of amniotic fluid. Fetal urination, lung fluid production and swallowing, and intramembranous absorption (into the fetal vascular compartment) make significant contributions to fluid movement in late gestation; other factors (eg, saliva production) make minimal contributions. The relative contribution of each route of fluid exchange varies across gestation. Variations in fetal body fluid or endocrine homeostasis also affect the volume of fetal urine production, swallowing, and lung liquid secretion. During the last trimester, urine output is equivalent to approximately 30 percent of fetal body weight, swallowing 20 to 25 percent, lung secretions 10 percent (one-half of lung secretions are swallowed and the other half are excreted into the amniotic fluid), while oral-nasal secretion and transmembranous flow (directly into the maternal compartment) represent &lt;1 percent of fetal body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/9\">",
"     9",
"    </a>",
"    ]. The near-term fetus excretes 500 to 1200 mL of urine and swallows 210 to 760 mL of amniotic fluid each day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, relatively minor daily changes in fetal urine production or swallowing can result in marked changes in amniotic fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Excessive accumulation of amniotic fluid is typically related to decreased fetal swallowing or increased fetal urination.",
"   </p>",
"   <p>",
"    The physiology of normal amniotic fluid production and volume regulation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=see_link\">",
"     \"Physiology of amniotic fluid volume regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of identifying the etiology of polyhydramnios depends upon its severity. In one series, as an example, the cause was determined in only 17 percent of pregnancies with mild polyhydramnios, but in 91 percent of those with moderate or severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/4\">",
"     4",
"    </a>",
"    ]. Historically, approximately 60 percent of cases were considered idiopathic. The etiology of the remaining cases usually fell into one of the following categories [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/4,5,13-20\">",
"     4,5,13-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal malformations and genetic disorders (8 to 45 percent)",
"     </li>",
"     <li>",
"      Maternal diabetes mellitus (5 to 26 percent)",
"     </li>",
"     <li>",
"      Multiple gestation (8 to 10 percent)",
"     </li>",
"     <li>",
"      Fetal anemia (1 to 11 percent)",
"     </li>",
"     <li>",
"      Other (eg, congenital viral infection, Bartter syndrome, hydrops fetalis, neuromuscular disorders, maternal hypercalcemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advances in prenatal sonographic diagnosis of congenital anomalies and prevention of Rh(D) isoimmunization over the past few decades have changed the relative frequencies of these etiologies, and reduced the number of idiopathic cases. In a retrospective study of 272 cases of polyhydramnios diagnosed between 2004 and 2010, only 43 percent were considered idiopathic antenatally, but an anomaly was found after birth in 10 percent of these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital anomalies in all organ systems have been linked with excessive accumulation of amniotic fluid. The most common structural defects associated with polyhydramnios are those that interfere with fetal swallowing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    absorption of fluid, such as gastrointestinal obstruction due to duodenal, esophageal, or intestinal atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Decreased swallowing may also be due to neuromuscular disorders, such as anencephaly or myotonic dystrophy, or to secondary obstruction of the gastrointestinal tract from massive unilateral dysplastic kidneys.",
"   </p>",
"   <p>",
"    The combination of intrauterine growth restriction and polyhydramnios is suggestive of trisomy 18, especially if there is abnormal hand positioning. The excess fluid in these fetuses may be related to difficulty swallowing or intestinal abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H11#H11\">",
"     \"Congenital cytogenetic abnormalities\", section on 'Trisomy 18 syndrome'",
"    </a>",
"    .) Other aneuploidies have also been associated with polyhydramnios, most commonly trisomy 21.",
"   </p>",
"   <p>",
"    Increased urine production may occur with a high cardiac output state, or, rarely, from entities such as fetal Bartter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/22\">",
"     22",
"    </a>",
"    ]. Ultrasound assessment of fetal urine production may be of value in differentiating causes of increased amniotic fluid volume, as urine production is increased in cases with increased AFI without fetal anomalies, but not in those with increased AFI and fetal anomalies involving decreased gastrointestinal absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High cardiac output may be related to fetal anemia (eg, isoimmunization, parvovirus infection, fetomaternal hemorrhage, alpha-thalassemia, glucose-6-phosphatase deficiency) or twin-to-twin transfusion syndrome. It is not clear whether polyhydramnios in diabetic pregnancies is caused by fetal glucosuria or other mechanisms, but poor glycemic control and large fetal size correlate with greater increases in amniotic fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/24\">",
"     24",
"    </a>",
"    ]. Decreased fetal swallowing or an imbalance in water movement between the maternal and fetal compartments are other possibilities.",
"   </p>",
"   <p>",
"    Maternal diabetes may be associated with increased amniotic fluid. As fetal glycosuria is the likely etiology, polyhydramnios is more often associated with poor diabetes control. In one study, among 314 women with pregestational diabetes with a singleton pregnancy beyond 24 weeks of gestation, the incidence of polyhydramnios was 18.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/25\">",
"     25",
"    </a>",
"    ]. Pregnancies complicated by polyhydramnios were associated with increased hemoglobin A1c. Despite this, there was no significant increase in adverse perinatal outcome in these pregnancies.",
"   </p>",
"   <p>",
"    Children born to pregnancies complicated by unexplained severe polyhydramnios should be assessed by a pediatrician over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In one report, 19 of 24 infants had a normal outcome; West syndrome, polyuria and pulmonary stenosis were diagnosed in three children during follow-up, and there were two perinatal deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the diagnosis of polyhydramnios is based upon sonographic visualization of increased amniotic fluid volume. This may be qualitative or quantitative, but generally has a strong subjective component. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few large studies in women with polyhydramnios comparing the various methods of amniotic fluid assessment against a gold standard (ie, dye dilution) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. One such study compared amniotic fluid index (AFI) 25 cm to a dye standard for diagnosis of polyhydramnios and reported sensitivity, specificity, and positive and negative predictive values (PPV, NPV) of 30, 98, 57, and 93 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/30\">",
"     30",
"    </a>",
"    ]. A two-diameter amniotic pocket volume greater than 50 cm(2) performed slightly better, with sensitivity, specificity, PPV and NPV of 38, 97, 62, and 94 percent, respectively. Another study by the same group found the sensitivity, specificity, PPV, and NPV of a single deepest pocket greater than 8 cm was 29, 94, 45, and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, all available noninvasive diagnostic tests for polyhydramnios perform relatively poorly.",
"   </p>",
"   <p>",
"    If there is a subjective impression of polyhydramnios, we recommend an objective measure such as amniotic fluid index be performed. Objective indices are standardized and provide a measurement that can be followed on serial examinations, even if sensitivity and positive predictive value are low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive sonographic evaluation should be performed to determine whether fetal anomalies or fetal hydrops is present. In the large series described above, the frequency of an anomalous infant with mild, moderate, and severe polyhydramnios was 8, 12, and 31 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/5\">",
"     5",
"    </a>",
"    ]. Overall, 80 percent of anomalous infants were detected prenatally. Anomalies most often missed included tracheoesophageal fistula, cardiac septal defects, and cleft palate.",
"   </p>",
"   <p>",
"    Laboratory evaluation may include, as clinically indicated: glucose challenge test to screen for gestational diabetes, Kleihauer-Betke to look for fetomaternal hemorrhage, maternal serology to determine exposure to infectious agents (eg, syphilis, parvovirus, cytomegalovirus, toxoplasmosis, rubella), and appropriate tests for hereditary anemias or metabolic abnormalities (eg, alpha thalassemia). Gestational diabetes is suggested by the presence of macrosomia, but no abnormal intrafetal fluid. Severely anemic fetuses often have pleural or pericardial fluid accumulation, ascites,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin edema. Peak systolic velocity in the middle cerebral artery is often elevated &gt;1.5 multiples of the median with moderate or severe anemia. Congenital infection may be associated with maternal signs or symptoms of infection and fetal abnormalities (eg, hydrops, fetal growth restriction, hepatosplenomegaly, cerebral ventriculomegaly, intracranial and intraabdominal calcifications, hyperechogenic fetal bowel, ascites). In the absence of any signs and symptoms, TORCH titers are unlikely to identify recent infection in patients with polyhydramnios, especially if diagnosed in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/31\">",
"     31",
"    </a>",
"    ]. (See individual topic reviews on each subject).",
"   </p>",
"   <p>",
"    Amniocentesis can be undertaken for karyotype analysis and, if indicated, detection of congenital infection by polymerase chain reaction (PCR) testing. Karyotype analysis is recommended when congenital anomalies are detected, given the high risk of aneuploidy. In one large representative series, the prevalence of aneuploidy in anomalous fetuses with polyhydramnios was 10 percent (95% CI 5-19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/5\">",
"     5",
"    </a>",
"    ]. Whether karyotype should be obtained in the absence of anomalies or growth restriction is more controversial. The likelihood of aneuploidy is much lower in the setting of a normal sonogram. In this same series, the prevalence was 1 percent (95% CI 0.4- 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/5\">",
"     5",
"    </a>",
"    ], a range consistent with that reported in other smaller and older series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/29,32-35\">",
"     29,32-35",
"    </a>",
"    ]. We recommend karyotype analysis be considered in cases of severe polyhydramnios because of the increased risk of aneuploidy noted in most series, the possibility that anomalies were not detected by sonographic examination, and the low risk of the procedure.",
"   </p>",
"   <p>",
"    The etiology and diagnostic evaluation of hydrops fetalis and twin-to-twin transfusion syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link\">",
"     \"Twin pregnancy: Prenatal issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyhydramnios has been associated with an increased risk of several obstetrical complications related to uterine overdistention:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maternal respiratory compromise",
"     </li>",
"     <li>",
"      Preterm labor",
"     </li>",
"     <li>",
"      Premature rupture of membranes",
"     </li>",
"     <li>",
"      Fetal malposition",
"     </li>",
"     <li>",
"      Umbilical cord prolapse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      postpartum uterine atony",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, idiopathic polyhydramnios has been linked to fetal macrosomia (due to the association with maternal diabetes), an increase in the risk of adverse pregnancy outcomes, and a two- to five-fold increase in the risk of perinatal mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Adverse pregnancy outcomes associated with polyhydramnios include increased risks of pregnancy induced hypertension, urinary tract infection, need for cesarean delivery, nuchal cord, low five-min Apgar scores, and newborn intensive care unit admission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/1,36,38\">",
"     1,36,38",
"    </a>",
"    ]. The risk of an adverse pregnancy outcome varies according to the underlying etiology of the excessive fluid accumulation and increases with increasing severity of polyhydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/1-3,8\">",
"     1-3,8",
"    </a>",
"    ]. The association of a small for gestational age fetus with polyhydramnios has a particularly poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotic fluid volume reduction may be considered to relieve maternal discomfort and prolong pregnancy; however, this intervention has never been evaluated in randomized or controlled studies. Methods for reducing excessive amniotic fluid volume include amnioreduction and maternal administration of prostaglandin synthetase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Amnioreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus concerning how much fluid to remove, how rapidly to remove the fluid, use of tocolytic medications, or use of antibiotics. A common technique is to cleanse the site with a surgical scrub and then administer local anesthesia into the skin and subcuticular tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/42\">",
"     42",
"    </a>",
"    ]. An 18-gauge spinal needle is inserted with the tip directed in a caudal direction and the hub of the needle positioned cranially so as to prevent the needle tip from touching the uterine wall as the uterus becomes smaller with decompression. Hard-walled arterial line tubing with a three way stopcock is attached to the needle and connected to a vacuum suction bottle. The fluid may be suctioned directly into the container or, alternatively, removed with a 50 mL syringe under controlled suction, but this can be tedious when there is a lot of fluid. A reasonable guideline is to remove the fluid no faster than 1000 mL over 20 minutes and not to remove more than 5 liters at one time. The procedure is terminated when the AFI is normalized (generally 15 to 20 cm) or when intraamniotic pressure is less than 20 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/43\">",
"     43",
"    </a>",
"    ]. Sometimes the procedure will need to be terminated early because of patient discomfort, a clogged needle, or membrane separation. We do not use antibiotic prophylaxis routinely, and initiate tocolytic drugs only if increased contractions occur.",
"   </p>",
"   <p>",
"    On average, two procedures are needed to reduce amniotic fluid volume chronically, although some patients require many more [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. One case report described 12 amnioreductions which removed a total of 21,600 mL of fluid; the infant was diagnosed with West syndrome at follow-up 16 months after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following amnioreduction, we suggest monitoring amniotic fluid volume every one to three weeks, as indicated by the severity of the process. Amnioreduction can be repeated if severe polyhydramnios recurs. Complications occur in 1 to 3 percent of procedures and include labor, abruptio placentae, premature rupture of membranes, hypoproteinemia, and chorioamnionitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. In cases presenting with uterine contractions, amnioreduction has reduced symptoms within a few hours of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prostaglandin synthetase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandin synthetase inhibitors may stimulate fetal secretion of arginine vasopressin and facilitate vasopressin-induced renal antidiuretic responses, and reduced renal blood flow, thereby reducing fetal urine flow. These agents also may impair production or enhance reabsorption of lung liquid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/46\">",
"     46",
"    </a>",
"    ]. The reduction of amniotic fluid volume occurs in pregnancies with both normal or abnormal amniotic fluid volume at baseline.",
"   </p>",
"   <p>",
"    Six series have reported the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    to treat polyhydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/47\">",
"     47",
"    </a>",
"    ]. Indomethacin is started at 25 mg orally four times daily. If there is no reduction in amniotic fluid volume after two or three days, then the dose is gradually increased up to 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/39\">",
"     39",
"    </a>",
"    ]. The drug is tapered when there is a reduction in amniotic fluid volume, and stopped when polyhydramnios is no longer severe. A literature review found this therapy to be effective in 48 of 52 patients studied [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal side effects, such as nausea, esophageal reflux, gastritis, and emesis, are seen in approximately 4 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    for preterm labor. Alterations of maternal cardiovascular physiology are minimal. Platelet dysfunction may occur with the use of nonsteroidal antiinflammatory drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary fetal concern with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is constriction of the ductus arteriosus. Serial fetal echocardiographic evaluation with Doppler is recommended at intervals of two days to one week if the duration of therapy exceeds 48 hours. Sonographic signs of ductal narrowing include tricuspid regurgitation and right ventricular dysfunction. Possible links with neonatal necrotizing enterocolitis and intraventricular hemorrhage are more controversial. These are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link&amp;anchor=H1279823#H1279823\">",
"     \"Inhibition of acute preterm labor\", section on 'Cyclooxygenase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sulindac",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     Sulindac",
"    </a>",
"    is a nonsteroidal antiinflammatory drug that also results in reduction of amniotic fluid volume, but appears to have less of a constrictive effect on the fetal ductus than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. However, there are no clinical studies evaluating this agent for treatment of polyhydramnios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Future therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Future therapeutic approaches for polyhydramnios may include the use of intraamniotic pharmacologic agents to reduce fetal fluid production. In ovine pregnancy, intraamniotic administration of either AVP or DDAVP results in rapid fetal plasma absorption and a marked decrease in fetal urine flow [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/52\">",
"     52",
"    </a>",
"    ], although there is no effect on fetal swallowing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Modulation of the amniotic membrane aquaporin water channels, which have been reported to be altered in the amnion and chorion of patients with unexplained polyhydramnios, may represent a potential future therapeutic opportunity to normalize amniotic fluid volume (AFV) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24000148\">",
"    <span class=\"h2\">",
"     Antepartum fetal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated whether pregnancies complicated by polyhydramnios benefit from any method of antenatal surveillance. Given the increase in risk of adverse pregnancy outcomes and the two- to five-fold increase in risk of perinatal mortality in these cases, we advocate following these pregnancies with a program of fetal assessment. In the absence of high quality data, several approaches have been suggested, including Doppler flow velocimetry of the middle cerebral artery, nonstress tests, biophysical profiles, and contraction stress tests [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/36\">",
"     36",
"    </a>",
"    ]. We generally perform a nonstress test",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biophysical profile every one to two weeks, depending upon the severity of polyhydramnios. In assessment of the biophysical profile score, clinicians should be cautious not to attribute fetal well-being to a normal or increased amniotic fluid volume in patients in these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84177261\">",
"    <span class=\"h2\">",
"     Expectant management versus intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have compared the outcome of expectant management of idiopathic polyhydramnios to intervention. Therapeutic intervention for specific complications as they arise is the usual practice. Many idiopathic cases resolve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/1\">",
"     1",
"    </a>",
"    ]. We suggest treatment of polyhydramnios in singleton pregnancy only if it is severe and symptomatic: preterm labor or significant maternal discomfort. The management of polyhydramnios in twin-twin transfusion syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=see_link\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancies under 32 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;For severe symptomatic polyhydramnios at less than 32 weeks of gestation, we suggest amnioreduction (to normalize fluid volume) followed by treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    to maintain normal amniotic fluid volume without exposing the fetus to the risks of serial invasive procedures. As discussed above, indomethacin is started at 25 mg orally four times daily.",
"   </p>",
"   <p>",
"    During",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    therapy we monitor amniotic fluid volume at least weekly while titrating the indomethacin dose to amniotic fluid volume changes. If there is no reduction in amniotic fluid volume, then the dose is gradually increased to a maximum of 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/39\">",
"     39",
"    </a>",
"    ]. The drug is tapered when there is a reduction in amniotic fluid volume, and stopped when polyhydramnios is no longer severe. We obtain serial fetal echocardiographic evaluations if the duration of therapy exceeds 48 hours and the pregnancy is over 24 weeks of gestation. It may be possible to discontinue indomethacin treatment if severe polyhydramnios does not recur as the indomethacin is tapered. Indomethacin is discontinued no later than 32 to 34 weeks because of the risk of premature ductal constriction.",
"   </p>",
"   <p>",
"    Amniocentesis or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    treatment can be reinitiated if severe polyhydramnios recurs.",
"   </p>",
"   <p>",
"    One case of a 34-year-old woman presenting with acute recurrent polyhydramnios reported successful treatment with non-steroidal anti-inflammatory drugs (NSAID) and therapeutic amniocenteses with decreased amniotic fluid production from 30 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/56\">",
"     56",
"    </a>",
"    ]. Even after the discontinuation of NSAID treatment, the amniotic fluid volume remained normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pregnancies over 32 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;For severe symptomatic polyhydramnios after 32 weeks of gestation, we suggest amnioreduction alone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    is utilized only if the potential benefits (avoidance of serial amnioreduction procedures) are likely to exceed the risks of premature ductal closure and maternal side effects. As an example, indomethacin may be considered in select cases when the gestational age is between 32 and 34 weeks and severe symptomatic polyhydramnios persists despite at least one attempt at amnioreduction. In these pregnancies, serial fetal echocardiographic evaluation at least weekly is especially important if the duration of therapy exceeds 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;During labor, the fetal position is checked frequently to confirm vertex presentation as the excess amniotic fluid allows greater fetal mobility. Conversion to a breech, compound, or transverse presentation may occur.",
"   </p>",
"   <p>",
"    Spontaneous rupture of membranes can cause sudden severe uterine decompression with risk of cord prolapse or abruption. Gradual abdominal or transcervical amnioreduction with a needle may prevent these complications during labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no absolute contraindication to use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    or prostaglandins in cases of polyhydramnios, these agents should be used with caution. There is a marked increase in the incidence of postpartum hemorrhage related to atony in patients with polyhydramnios; use of uterine stimulants may increase this risk and that of amniotic fluid embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4808/abstract/47,57\">",
"     47,57",
"    </a>",
"    ]. However, we use prostaglandins for cervical ripening and oxytocin for induction, as clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyhydramnios is typically caused by decreased fetal swallowing or increased fetal urination. The most common etiologies are: fetal malformations and genetic disorders, maternal diabetes mellitus, multiple gestation, and fetal anemia. Rare causes include congenital viral infection or Bartter syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is a subjective impression of polyhydramnios, we suggest that an objective measure such as an AFI be performed. Objective indices are standardized and provide a measurement that can be followed on serial examinations, even though sensitivity and positive predictive value are suboptimal. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A comprehensive sonographic evaluation is recommended to determine whether fetal anomalies or fetal hydrops is present. Suggested laboratory evaluations depend upon sonographic findings and may include screening for gestational diabetes, Kleihauer-Betke to look for fetomaternal hemorrhage suggestive of fetal anemia, maternal serology to determine exposure to infectious agents (eg, syphilis, parvovirus, cytomegalovirus, toxoplasmosis, rubella), and appropriate tests for hereditary anemias or metabolic abnormalities (eg, alpha thalassemia). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend karyotype analysis in cases of severe polyhydramnios or if there are associated anatomic anomalies. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcome of pregnancies complicated by polyhydramnios varies according to the severity and underlying etiology of the excessive fluid accumulation. Possible complications include maternal respiratory compromise, preterm labor, premature rupture of membranes, fetal malposition, and umbilical cord prolapse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      postpartum uterine atony. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment for polyhydramnios in singleton pregnancy only if there is preterm labor or significant maternal discomfort (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The therapeutic option is determined by the gestational age, degree of discomfort, and sensitivity or contraindication to prostaglandin synthetase inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For severe symptomatic polyhydramnios at less than 32 weeks of gestation, we suggest amnioreduction (to normalize fluid volume) and treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      to maintain normal amniotic fluid volume (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pregnancies under 32 weeks'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      During indomethacin therapy we monitor amniotic fluid volume at least weekly and titrate the indomethacin dose to amniotic fluid volume changes. We also monitor ductal Doppler flow with increased surveillance after 28 weeks of gestation to look for early evidence of constriction. It may be possible to discontinue indomethacin treatment if polyhydramnios does not recur as the indomethacin is tapered. Indomethacin is discontinued no later than 32 weeks because of the risk of premature ductal constriction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prostaglandin synthetase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For severe symptomatic polyhydramnios after 32 weeks of gestation, we suggest amnioreduction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest not administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      because of the high risk of premature closure of the ductus arteriosus at this gestational age (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, in select cases, this risk may be outweighed by the risk associated with multiple amniocenteses or prematurity. In these cases, ductal Doppler flow should be followed at least weekly to detect early evidence of constriction. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pregnancies over 32 weeks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/1\">",
"      Golan A, Wolman I, Sagi J, et al. Persistence of polyhydramnios during pregnancy--its significance and correlation with maternal and fetal complications. Gynecol Obstet Invest 1994; 37:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/2\">",
"      Many A, Hill LM, Lazebnik N, Martin JG. The association between polyhydramnios and preterm delivery. Obstet Gynecol 1995; 86:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/3\">",
"      Smith CV, Plambeck RD, Rayburn WF, Albaugh KJ. Relation of mild idiopathic polyhydramnios to perinatal outcome. Obstet Gynecol 1992; 79:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/4\">",
"      Hill LM, Breckle R, Thomas ML, Fries JK. Polyhydramnios: ultrasonically detected prevalence and neonatal outcome. Obstet Gynecol 1987; 69:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/5\">",
"      Dashe JS, McIntire DD, Ramus RM, et al. Hydramnios: anomaly prevalence and sonographic detection. Obstet Gynecol 2002; 100:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/6\">",
"      Thompson O, Brown R, Gunnarson G, Harrington K. Prevalence of polyhydramnios in the third trimester in a population screened by first and second trimester ultrasonography. J Perinat Med 1998; 26:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/7\">",
"      Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol 1999; 94:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/8\">",
"      Pri-Paz S, Khalek N, Fuchs KM, Simpson LL. Maximal amniotic fluid index as a prognostic factor in pregnancies complicated by polyhydramnios. Ultrasound Obstet Gynecol 2012; 39:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/9\">",
"      Brace RA. Physiology of amniotic fluid volume regulation. Clin Obstet Gynecol 1997; 40:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/10\">",
"      Harding R, Bocking AD, Sigger JN, Wickham PJ. Composition and volume of fluid swallowed by fetal sheep. Q J Exp Physiol 1984; 69:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/11\">",
"      PRITCHARD JA. DEGLUTITION BY NORMAL AND ANENCEPHALIC FETUSES. Obstet Gynecol 1965; 25:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/12\">",
"      Pritchard JA. Fetal swallowing and amniotic fluid volume. Obstet Gynecol 1966; 28:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/13\">",
"      Phelan JP, Martin GI. Polyhydramnios: fetal and neonatal implications. Clin Perinatol 1989; 16:987.",
"     </a>",
"    </li>",
"    <li>",
"     Ledger, WF. Maternal infection with adverse fetal and newborn outcomes. In: Infection in the female. Philadelphia: Lea &amp; Febiger, 1986. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/15\">",
"      Queenan JT, Gadow EC. Polyhydramnios: chronic versus acute. Am J Obstet Gynecol 1970; 108:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/16\">",
"      MURRAY SR. HYDRAMNIOS: A STUDY OF 846 CASES. Am J Obstet Gynecol 1964; 88:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/17\">",
"      Ben-Chetrit A, Hochner-Celnikier D, Ron M, Yagel S. Hydramnios in the third trimester of pregnancy: a change in the distribution of accompanying fetal anomalies as a result of early ultrasonographic prenatal diagnosis. Am J Obstet Gynecol 1990; 162:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/18\">",
"      Stoll CG, Alembik Y, Dott B. Study of 156 cases of polyhydramnios and congenital malformations in a series of 118,265 consecutive births. Am J Obstet Gynecol 1991; 165:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/19\">",
"      Shani H, Sivan E, Cassif E, Simchen MJ. Maternal hypercalcemia as a possible cause of unexplained fetal polyhydramnion: a case series. Am J Obstet Gynecol 2008; 199:410.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/20\">",
"      Dorleijn DM, Cohen-Overbeek TE, Groenendaal F, et al. Idiopathic polyhydramnios and postnatal findings. J Matern Fetal Neonatal Med 2009; 22:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/21\">",
"      Abele H, Starz S, Hoopmann M, et al. Idiopathic polyhydramnios and postnatal abnormalities. Fetal Diagn Ther 2012; 32:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/22\">",
"      Sieck UV, Ohlsson A. Fetal polyuria and hydramnios associated with Bartter's syndrome. Obstet Gynecol 1984; 63:22S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/23\">",
"      Lee SM, Jun JK, Lee EJ, et al. Measurement of fetal urine production to differentiate causes of increased amniotic fluid volume. Ultrasound Obstet Gynecol 2010; 36:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/24\">",
"      Vink JY, Poggi SH, Ghidini A, Spong CY. Amniotic fluid index and birth weight: is there a relationship in diabetics with poor glycemic control? Am J Obstet Gynecol 2006; 195:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/25\">",
"      Idris N, Wong SF, Thomae M, et al. Influence of polyhydramnios on perinatal outcome in pregestational diabetic pregnancies. Ultrasound Obstet Gynecol 2010; 36:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/26\">",
"      Touboul C, Boileau P, Picone O, et al. Outcome of children born out of pregnancies complicated by unexplained polyhydramnios. BJOG 2007; 114:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/27\">",
"      Touboul C, Picone O, Levaillant JM, et al. Clinical application of fetal urine production rate in unexplained polyhydramnios. Ultrasound Obstet Gynecol 2009; 34:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/28\">",
"      Magann EF, Chauhan SP, Barrilleaux PS, et al. Amniotic fluid index and single deepest pocket: weak indicators of abnormal amniotic volumes. Obstet Gynecol 2000; 96:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/29\">",
"      Barnhard Y, Bar-Hava I, Divon MY. Is polyhydramnios in an ultrasonographically normal fetus an indication for genetic evaluation? Am J Obstet Gynecol 1995; 173:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/30\">",
"      Chauhan SP, Magann EF, Morrison JC, et al. Ultrasonographic assessment of amniotic fluid does not reflect actual amniotic fluid volume. Am J Obstet Gynecol 1997; 177:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/31\">",
"      Fayyaz H, Rafi J. TORCH screening in polyhydramnios: an observational study. J Matern Fetal Neonatal Med 2012; 25:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/32\">",
"      Landy HJ, Isada NB, Larsen JW Jr. Genetic implications of idiopathic hydramnios. Am J Obstet Gynecol 1987; 157:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/33\">",
"      Brady K, Polzin WJ, Kopelman JN, Read JA. Risk of chromosomal abnormalities in patients with idiopathic polyhydramnios. Obstet Gynecol 1992; 79:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/34\">",
"      Carlson DE, Platt LD, Medearis AL, Horenstein J. Quantifiable polyhydramnios: diagnosis and management. Obstet Gynecol 1990; 75:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/35\">",
"      Zahn CM, Hankins GD, Yeomans ER. Karyotypic abnormalities and hydramnios. Role of amniocentesis. J Reprod Med 1993; 38:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/36\">",
"      Magann EF, Chauhan SP, Doherty DA, et al. A review of idiopathic hydramnios and pregnancy outcomes. Obstet Gynecol Surv 2007; 62:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/37\">",
"      Erez O, Shoham-Vardi I, Sheiner E, et al. Hydramnios and small for gestational age are independent risk factors for neonatal mortality and maternal morbidity. Arch Gynecol Obstet 2005; 271:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/38\">",
"      Magann EF, Doherty DA, Lutgendorf MA, et al. Peripartum outcomes of high-risk pregnancies complicated by oligo- and polyhydramnios: a prospective longitudinal study. J Obstet Gynaecol Res 2010; 36:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/39\">",
"      Cabrol D, Landesman R, Muller J, et al. Treatment of polyhydramnios with prostaglandin synthetase inhibitor (indomethacin). Am J Obstet Gynecol 1987; 157:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/40\">",
"      Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 1989; 160:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/41\">",
"      Kirshon B, Mari G, Moise KJ Jr. Indomethacin therapy in the treatment of symptomatic polyhydramnios. Obstet Gynecol 1990; 75:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/42\">",
"      Elliott JP, Sawyer AT, Radin TG, Strong RE. Large-volume therapeutic amniocentesis in the treatment of hydramnios. Obstet Gynecol 1994; 84:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/43\">",
"      Fisk NM, Tannirandorn Y, Nicolini U, et al. Amniotic pressure in disorders of amniotic fluid volume. Obstet Gynecol 1990; 76:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/44\">",
"      Leung WC, Jouannic JM, Hyett J, et al. Procedure-related complications of rapid amniodrainage in the treatment of polyhydramnios. Ultrasound Obstet Gynecol 2004; 23:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/45\">",
"      Jauniaux E, Holmes A, Hyett J, et al. Rapid and radical amniodrainage in the treatment of severe twin-twin transfusion syndrome. Prenat Diagn 2001; 21:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/46\">",
"      Kramer WB, Van den Veyver IB, Kirshon B. Treatment of polyhydramnios with indomethacin. Clin Perinatol 1994; 21:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/47\">",
"      Harman CR. Amniotic fluid abnormalities. Semin Perinatol 2008; 32:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/48\">",
"      Moise KJ Jr. Polyhydramnios. Clin Obstet Gynecol 1997; 40:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/49\">",
"      Bartfield M, Carlan SJ. The safety and efficacy of prolonged outpatient sulindac to prevent the recurrence of preterm labor: a prospective double-blind study. Prim Care Update Ob Gyns 1998; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/50\">",
"      Kramer WB, Saade GR, Belfort M, et al. A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor. Am J Obstet Gynecol 1999; 180:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/51\">",
"      Peek MJ, McCarthy A, Kyle P, et al. Medical amnioreduction with sulindac to reduce cord complications in monoamniotic twins. Am J Obstet Gynecol 1997; 176:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/52\">",
"      Gilbert WM, Cheung CY, Brace RA. Rapid intramembranous absorption into the fetal circulation of arginine vasopressin injected intraamniotically. Am J Obstet Gynecol 1991; 164:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/53\">",
"      Kullama LK, Nijland MJ, Ervin MG, Ross MG. Intraamniotic deamino(D-Arg8)-vasopressin: prolonged effects on ovine fetal urine flow and swallowing. Am J Obstet Gynecol 1996; 174:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/54\">",
"      Mann SE, Dvorak N, Gilbert H, Taylor RN. Steady-state levels of aquaporin 1 mRNA expression are increased in idiopathic polyhydramnios. Am J Obstet Gynecol 2006; 194:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/55\">",
"      Zhu X, Jiang S, Hu Y, et al. The expression of aquaporin 8 and aquaporin 9 in fetal membranes and placenta in term pregnancies complicated by idiopathic polyhydramnios. Early Hum Dev 2010; 86:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/56\">",
"      Rode L, Bundgaard A, Skibsted L, et al. Acute recurrent polyhydramnios: a combination of amniocenteses and NSAID may be curative rather than palliative. Fetal Diagn Ther 2007; 22:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4808/abstract/57\">",
"      Kramer MS, Rouleau J, Baskett TF, et al. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet 2006; 368:1444.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6781 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4808=[""].join("\n");
var outline_f4_44_4808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Amnioreduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prostaglandin synthetase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sulindac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Future therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24000148\">",
"      Antepartum fetal monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84177261\">",
"      Expectant management versus intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancies under 32 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pregnancies over 32 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=related_link\">",
"      Physiology of amniotic fluid volume regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_44_4809="Pathophysiology of and immune response to Helicobacter pylori infection";
var content_f4_44_4809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of and immune response to Helicobacter pylori infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4809/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4809/contributors\">",
"     Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4809/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4809/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4809/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/44/4809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helicobacter pylori is highly adapted to the gastric environment where it lives within or beneath the gastric mucous layer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=see_link\">",
"     \"Bacteriology and epidemiology of Helicobacter pylori infection\"",
"    </a>",
"    .) The bacterium generally does not invade gastroduodenal tissue. Instead, it renders the underlying mucosa more vulnerable to acid peptic damage by disrupting the mucous layer, liberating enzymes and toxins, and adhering to the gastric epithelium. In addition, the host immune response to H. pylori incites an inflammatory reaction which further perpetuates tissue injury.",
"   </p>",
"   <p>",
"    The chronic inflammation induced by H. pylori upsets gastric acid secretory physiology to varying degrees and leads to chronic gastritis which, in most individuals is asymptomatic and does not progress (",
"    <a class=\"graphic graphic_picture graphicRef63916 graphicRef58872 \" href=\"UTD.htm?19/23/19832\">",
"     picture 1A-B",
"    </a>",
"    ). In some cases, however, altered gastric secretion coupled with tissue injury leads to peptic ulcer disease, while in other cases, gastritis progresses to atrophy, intestinal metaplasia, and eventually gastric carcinoma or rarely, due to persistent immune stimulation of gastric lymphoid tissue, gastric lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=see_link\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link\">",
"     \"Metaplastic (chronic) atrophic gastritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, the pathophysiology of H. pylori infection and its eventual clinical outcome should be viewed as a complex interaction between the host and the bacterium. This interaction is influenced by the environment and modulated by a number of largely as yet unidentified factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology of H. pylori infection as it relates to gastrointestinal disease in general will be reviewed here. The role of H. pylori in specific disease processes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=see_link\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACTERIAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue injury induced by H. pylori depends upon bacterial attachment and the subsequent release of enzymes and other microbial products that can cause cellular damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bacterial attachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori",
"    <strong>",
"     exclusively",
"    </strong>",
"    colonizes gastric type epithelium, which suggests specific recognition of cell type by the bacterium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/3\">",
"     3",
"    </a>",
"    ]. Electron microscopy has confirmed the presence of tight adherence of H. pylori to the gastric cell surface through formation of membrane attachment pedestals similar to those described with enteropathogenic Escherichia coli [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This process requires that bacterial adhesins recognize and specifically bind to host receptors expressed on the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/3\">",
"     3",
"    </a>",
"    ]. The attachment process may morphologically or functionally alter the epithelial cell or activate certain bacterial functions making them more toxic. At the site of adherence, bacterial membrane proteins coded by genes contained in the cag pathogenicity island (PAI) open channels in the epithelial cell membrane that enable direct contact of bacterial factors with the cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial attachment is partially mediated by a number of adhesins and outer membrane proteins. Three Hop proteins have been implicated in the pathogenesis of H. pylori infection, BabA (HopS), OipA (HopH), and SabA (HopP) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/7\">",
"     7",
"    </a>",
"    ]. BabA, the best characterized of the three adhesin proteins, mediates binding to fucosylated Lewis b (Le(b)) blood group antigens on host cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/8\">",
"     8",
"    </a>",
"    ]. OipA may serve as an adhesin but it also promotes inflammation by increasing IL-8 expression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/9\">",
"     9",
"    </a>",
"    ]. SabA mediates binding to glycoconjugates containing sialic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/10\">",
"     10",
"    </a>",
"    ]. Replacement of nonsialylated Lewis antigens by sialylated Le(x) or Le(a) has been associated with H. pylori induced gastric inflammation and cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the role of Lewis antigen expression in bacterial attachment is unclear. Nevertheless, the homologous structures of H. pylori lipopolysaccharide and host LewisX antigen may lead to an autoimmune response with subsequent cell injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. H. pylori can also bind to class II MHC molecules on the surface of gastric epithelial cells and induce apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/14\">",
"     14",
"    </a>",
"    ]. In fact, binding of the organism's urease to surface class II MHC is itself sufficient to induce apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Release of enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori elaborates several enzymes that can cause cellular damage by direct or indirect mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urease accounts for over 5 percent of the organism's total protein weight [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/16\">",
"       16",
"      </a>",
"      ]. Urea, when hydrolyzed by bacterial urease, can form compounds such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"       ammonium chloride",
"      </a>",
"      and monochloramine that can directly damage epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition, the urease enzyme itself is antigenic, activates the host immune system, and indirectly produces injury by stimulating inflammatory cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bacterial phospholipases can alter the phospholipid content of the gastric mucosal barrier, changing its surface tension, hydrophobicity, and permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/18\">",
"       18",
"      </a>",
"      ]. The conversion of lecithin to lysolecithin (a toxic compound) by phospholipase A2 can lead to cell injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/18\">",
"       18",
"      </a>",
"      ], while lipolysis can disrupt the structure and integrity of gastric mucus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      H. pylori produces more catalase enzyme than most other bacteria. This enzyme, an antioxidant, may protect the organism from toxic oxygen metabolites liberated by activated neutrophils and allow it to survive and proliferate in an inflamed and damaged gastric mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/18,20\">",
"       18,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bacterial proteolytic enzyme activity can further degrade mucus. However, the importance of proteolysis remains controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bacterial strain differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional differences exist between strains of H. pylori that may relate to virulence and tissue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     CagA and VacA",
"    </span>",
"    &nbsp;&mdash;&nbsp;One such difference is expression of an 87 kilodalton (kd) vacuolating cytotoxin (VacA) which causes cell injury in vitro and gastric tissue damage in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. All H. pylori contain the gene coding for VacA; however, only those strains that encode the cytotoxin-associated gene (cag) pathogenicity island (PAI), including cytotoxin-associated gene A (CagA), coding for a 128 to 140 kd protein (CagA), coexpress VacA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/22\">",
"     22",
"    </a>",
"    ]. VacA behaves as a passive urea transporter that is potentially capable of increasing the permeability of the gastric epithelium to urea, thereby creating a favorable environment for H. pylori infectivity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/24\">",
"     24",
"    </a>",
"    ]. Virulence of VacA appears to depend upon the function of a tyrosine phosphatase receptor in gastric epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/25\">",
"     25",
"    </a>",
"    ]. H pylori strains with different VacA alleles have differing toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CagA is not cytotoxic but is antigenic and can be detected serologically [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/27\">",
"     27",
"    </a>",
"    ]. Its function is unknown but, since it is necessary for VacA expression, it may play a role in transcription, excretion, or function of the VacA cytotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/27\">",
"     27",
"    </a>",
"    ]. H. pylori can translocate its CagA protein into gastric epithelial cells via a type IV secretory apparatus. There it is tyrosine phosphorylated and possibly plays a role in host cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virulent strains of H. pylori encode cag PAI, which expresses a type IV secretion system (T4SS). This T4SS forms a syringe-like pilus structure for the injection of virulence factors such as the CagA effector protein into host target cells. This is achieved by a number of T4SS proteins, including CagI, CagL, CagY and CagA, which by itself binds the host cell integrin member &beta;(1) followed by delivery of CagA across the host cell membrane. CagA is not cytotoxic but is antigenic and can be detected serologically [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/27\">",
"     27",
"    </a>",
"    ]. A role of CagA interaction with phosphatidylserine has also been shown to be important for the injection process. After delivery, CagA becomes phosphorylated by oncogenic tyrosine kinases and mimics a host cell factor for the activation or inactivation of some specific intracellular signalling pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/27-31\">",
"     27-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strains producing VacA and CagA cause more intense tissue inflammation and induce cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/22,23,32\">",
"     22,23,32",
"    </a>",
"    ]. Two other genes (picA and picB, now termed CagE) which are cotranscribed and genetically linked to cagA share homology with genes coding for toxins in other known pathogenic bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/22,33\">",
"     22,33",
"    </a>",
"    ]. The gene product of picB (CagE) induces the release of epithelial cytokines, including interleukin-8 (IL-8) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/22,33\">",
"     22,33",
"    </a>",
"    ]. This effect appears to be mediated by nuclear factor kappa B, which activates transcription of IL-8 MRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, bacteria that express CagA are potent inducers of IL-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of CagA positivity is demonstrated in two different disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 85 to 100 percent of patients with duodenal ulcers have CagA+ strains, compared to 30 to 60 percent of infected patients who do not develop ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/37\">",
"       37",
"      </a>",
"      ]. Cag E positivity has also been associated with gastroduodenal disease in adults and children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CagA strains are associated with a higher frequency of precancerous lesions and gastric cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/40\">",
"       40",
"      </a>",
"      ]. The risk of malignancy may be related to specific amino acid sequences (EPIYA) in the CagA protein [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"       \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23985291\">",
"    <span class=\"h3\">",
"     Other virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to CagA, several other H. pylori virulence factors have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/42-48\">",
"     42-48",
"    </a>",
"    ]. The strength of these associations has not been well defined in large populations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Induced by contact with epithelium\" (iceA) has been associated with peptic ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/42,45,46\">",
"       42,45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Blood group antigen-binding adhesin\" (babA2) has been associated with duodenal ulcers and gastric cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Outer inflammatory protein\" (oipA) has been associated with duodenal ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of the virulence factors described above can coexist in the same H. pylori strains, making it unclear as to which factors might be most important. In addition, as noted above, expression of CagA is associated with both gastric cancer and duodenal ulcer, yet these two disorders rarely, if ever, coexist thereby minimizing the significance of this \"virulence factor\" in understanding disease pathogenesis.",
"   </p>",
"   <p>",
"    One study suggested that the oipA status may be a better predictor of H. pylori virulence than any of the other previously described virulence factors. The study included 247 H. pylori infected patients (86 with gastritis, 86 with a duodenal ulcer, and 75 with gastric carcinoma) in whom H. pylori isolates were tested for the other H. pylori virulence factors discussed above. On multivariate analysis, only oipA status remained an independent predictor of H. pylori density, mucosal inflammation, and high mucosal IL-8 levels. However, the actual biological significance of these observations is unknown. Adaptation to gastric conditions is enabled by phase variation of genes encoding outer membrane proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INFLAMMATORY RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although H. pylori is a noninvasive organism, it stimulates a robust inflammatory and immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. A variety of factors may contribute to these changes, which are described below. Bacterial colonization, persistence and virulence, and resulting innate and adaptive host immune responses are all important in the pathogenesis of H. pylori related disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/7,52,53\">",
"     7,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The organism produces a number of antigenic substances, including heat shock protein, urease, and lipopolysaccharide, all of which can be taken up and processed by lamina propria macrophages and activate T-cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/51,54\">",
"       51,54",
"      </a>",
"      ]. Cellular disruption, especially adjacent to epithelial tight junctions, undoubtedly enhances antigen presentation to the lamina propria and facilitates immune stimulation. The net result is increased production of inflammatory cytokines such as IL-1, IL-6, tumor necrosis factor alpha (TNF alpha), and most notably, IL-8 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/35,50,55,56\">",
"       35,50,55,56",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Interleukin-8'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A B cell response to H. pylori (with production of IgG and IgA antibodies) occurs locally in the gastroduodenal mucosa and systemically. The role of local antibodies in producing tissue injury or modulating inflammation in H. pylori infection remains controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Prolonged stimulation of gastric B cells by activated T cells can lead to MALT lymphoma in rare cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"       \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    T cells are also activated during infection and their cytokines boost bacterial binding (by inducing class II MHC). While T cells are recruited to the infected gastric mucosa, they appear to be hyporesponsive. B7-H1 (programmed death-1 ligand 1), a member of B7 family of proteins associated with T cell inhibition, appears to be involved in the suppression of T cell proliferation and IL-2 synthesis during H. pylori infection, and thus may contribute to its chronicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different T helper cell subsets can be distinguished by characteristic profiles of cytokine secretion. Th1 cells promote cell-mediated immune responses through elaboration of TNF alpha and IFN gamma. Th2 cells produce Il-4, IL-10 and TGF beta. It appears that during H. pylori infection the T-cell immunity is inappropriately skewed toward a Th1 response that promotes epithelial cell inflammatory cytokine production (IL-8 stimulated by IFN gamma and TNF alpha) and directly impacts epithelial apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H. pylori infection induces a marked increase in the flux of leukocytes and in the appearance of platelet and leukocyte-platelet aggregates in gastric venules in a murine model [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/60\">",
"       60",
"      </a>",
"      ]. Circulating platelet aggregates and activated platelets were also detected in patients infected with H. pylori, suggesting that platelet activation and aggregation contribute to the associated microvascular dysfunction and inflammatory cell recruitment. Platelet aggregation mediated by an H. pylori interaction with von Willebrand factor is speculated to contribute to infection related ulcer disease but also possibly non-GI manifestations of infection such as cardiovascular disease and idiopathic thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Not all H. pylori infected individuals develop clinical disease. Host genetics are important in determining the physiologic and clinical response to infection. Host polymorphism of IL-1 beta (and possibly IL-10) appears to determine the degree of inflammatory response to infection, resulting alteration in acid secretion (hyper or hypo secretion), and risk for subsequent gastric cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. One series of meta-analyses investigated genes coding for the interleukin (IL) proteins (IL1B, IL1RN, IL8, and IL10) and for TNF alpha. Gastric cancers were stratified by histologic subtype and anatomic subsite, by H. pylori infection status, by geographic location (Asian or non-Asian study population), and by a quantitative index of study quality. Results consistently supported increased cancer risk for IL1RN2 carriers; the increased risk was specific to non-Asian populations and was seen for intestinal and diffuse cancers, distal cancers, and, to a lesser extent, cardia cancers. In Asian populations, reduced risk was observed in association with IL1B-31C carrier status. These results indicate the importance of stratification by anatomic site, histologic type, H. pylori infection, and country of origin. Study quality considerations, both laboratory and epidemiologic, can also affect results and may explain, in part, the variability in results published to date [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Interleukin-8",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research has centered on epithelial IL-8 production induced by different strains of H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/35,66\">",
"     35,66",
"    </a>",
"    ]. IL-8 is a potent chemotactic factor, activates neutrophils, and recruits acute inflammatory cells into the mucosa. H. pylori appears to activate transcription factor NF-kB (nuclear factor kappa B), which in turn increases IL-8 production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/34,67\">",
"     34,67",
"    </a>",
"    ]. NF-kB also regulates the expression of additional inflammatory response genes, and may play a role in the mucosal epithelial response to other bacterial infections in addition to H. pylori.",
"   </p>",
"   <p>",
"    Bacteria that express CagA and VacA are more potent inducers of IL-8; however, the gene primarily responsible for IL-8 induction is picB (now renamed CagE), which is located upstream of the CagA gene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     CagA/VacA-positive",
"    </span>",
"    strains are also more often found in patients with clinical manifestations of H. pylori infection, indirectly suggesting that IL-8 may play an important pathophysiologic role in gastroduodenal disease.",
"   </p>",
"   <p>",
"    TNF alpha can also augment IL-8 production by the inflamed mucosa. Following successful eradication of H. pylori, mucosal levels of mRNA for both TNF alpha and IL-8 are reduced in parallel with the decline in local inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Survival of H. pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori itself is in part able to survive this inflammatory onslaught by producing the enzyme, catalase. This enzyme neutralizes the damaging reactive oxygen metabolites liberated by neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/18\">",
"     18",
"    </a>",
"    ]. With time, the host appears to downregulate the acute inflammatory response, making it easier for the organism to persist and proliferate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTIBODY RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infected individuals systemically produce specific antibodies to a variety of H. pylori antigens. The antibody response changes as infection progresses from an acute to a chronic stage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of IgM antibodies is an insensitive indicator of acute infection and generally is not clinically useful, even in children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgA and IgG antibodies are produced in response to infection, remain present as long as infection is active, and quantitatively decrease after infection is cured [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to CagA protein are detectable in gastric tissue and serum and permit the identification of infection with presumably more virulent organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of local antibodies in the immunopathogenesis of gastroduodenal mucosal injury is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/50\">",
"     50",
"    </a>",
"    ]. Virtually all infected persons have a specific gastric mucosal IgA and IgG response. IgA antibodies may modulate mucosal injury by inhibiting antigen uptake, disrupting bacterial adherence and motility, and neutralizing various toxins. IgG presumably augments inflammatory injury by activating complement and facilitating neutrophil activation.",
"   </p>",
"   <p>",
"    An antibody response may also be seen against autoantigens, including IL-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/74\">",
"     74",
"    </a>",
"    ], antral epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], and homologous host and bacterial epitopes (eg, LewisX, lipopolysaccharide, and heat shock protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/50\">",
"     50",
"    </a>",
"    ]. The immunoglobulin specificity of MALT lymphoma may be for such autoantigens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the mucosal immune response to H. pylori leads to tissue injury, it is also key to vaccination strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. One could question if effective vaccination is possible since the organism can successfully evade the immune response to natural infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/80\">",
"     80",
"    </a>",
"    ]. Nevertheless, preliminary studies suggest that preventive vaccination may be feasible. Immunization with crude sonicates of bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/81,82\">",
"     81,82",
"    </a>",
"    ] and more recently recombinant subunits of urease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/83,84\">",
"     83,84",
"    </a>",
"    ] and catalase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/85\">",
"     85",
"    </a>",
"    ] protect animals from H. pylori exposure. Human vaccines have undergone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/84,86\">",
"     84,86",
"    </a>",
"    ] and continue to undergo clinical testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A remaining problem is the development of a suitable and effective adjuvant with which to deliver bacterial antigens to the host [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/80\">",
"     80",
"    </a>",
"    ]. Cholera toxin, a useful vaccine adjuvant in animal studies, is not practical in humans for obvious reasons.",
"   </p>",
"   <p>",
"    Studies on vaccination have expanded to the area of therapeutic immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4809/abstract/80,88\">",
"     80,88",
"    </a>",
"    ]. A therapeutic vaccine could boost the natural immune response and facilitate spontaneous bacterial eradication or enhance the effectiveness of antibiotic regimens. A successful therapeutic vaccine would obviate the widespread use of antibiotics and minimize the development of antibiotic-resistant H. pylori organisms. Unfortunately, the promise of vaccines has not been met after more than two decades of research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathophysiology of H. pylori infection and its eventual clinical outcome should be viewed as a complex interaction between the host and the bacterium. This interaction is influenced by the environment and modulated by a number of largely as yet unidentified factors.",
"     </li>",
"     <li>",
"      Tissue injury induced by H. pylori depends upon bacterial attachment and the subsequent release of enzymes and other microbial products that can cause cellular damage. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bacterial factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional differences exist between strains of H. pylori that may relate to virulence and tissue damage. However, many of the virulence factors can coexist in the same H. pylori strains, making it unclear as to which factors might be most important. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bacterial strain differences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although H. pylori is a noninvasive organism, it stimulates a robust inflammatory and immune response. Bacterial colonization, persistence and virulence, and resulting innate and adaptive host immune responses are all important in the pathogenesis of H. pylori related disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Inflammatory response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/1\">",
"      Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/2\">",
"      Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006; 130:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/3\">",
"      Logan RP. Adherence of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/4\">",
"      Dytoc M, Gold B, Louie M, et al. Comparison of Helicobacter pylori and attaching-effacing Escherichia coli adhesion to eukaryotic cells. Infect Immun 1993; 61:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/5\">",
"      Noach LA, Rolf TM, Tytgat GN. Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa. J Clin Pathol 1994; 47:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/6\">",
"      Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996; 93:14648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/7\">",
"      Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/8\">",
"      Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/9\">",
"      Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A 2000; 97:7533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/10\">",
"      Mahdavi J, Sond&eacute;n B, Hurtig M, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/11\">",
"      Sakamoto S, Watanabe T, Tokumaru T, et al. Expression of Lewisa, Lewisb, Lewisx, Lewisy, siayl-Lewisa, and sialyl-Lewisx blood group antigens in human gastric carcinoma and in normal gastric tissue. Cancer Res 1989; 49:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/12\">",
"      Moran AP. The role of lipopolysaccharide in Helicobacter pylori pathogenesis. Aliment Pharmacol Ther 1996; 10 Suppl 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/13\">",
"      Wang G, Ge Z, Rasko DA, Taylor DE. Lewis antigens in Helicobacter pylori: biosynthesis and phase variation. Mol Microbiol 2000; 36:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/14\">",
"      Fan X, Crowe SE, Behar S, et al. The effect of class II major histocompatibility complex expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells: a mechanism for T helper cell type 1-mediated damage. J Exp Med 1998; 187:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/15\">",
"      Fan X, Gunasena H, Cheng Z, et al. Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J Immunol 2000; 165:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/16\">",
"      Hu LT, Mobley HL. Purification and N-terminal analysis of urease from Helicobacter pylori. Infect Immun 1990; 58:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/17\">",
"      Mobley HL. The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration. Aliment Pharmacol Ther 1996; 10 Suppl 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/18\">",
"      Nilius M, Malfertheiner P. Helicobacter pylori enzymes. Aliment Pharmacol Ther 1996; 10 Suppl 1:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/19\">",
"      Slomiany BL, Kasinathan C, Slomiany A. Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol). Am J Gastroenterol 1989; 84:1273.",
"     </a>",
"    </li>",
"    <li>",
"     Hazell SL. Urease and catalase as virulence factors of Helicobacter pylori. In: Helicobacter pylori 1990, Menge H, Gregor M, Tytgat GN, et al (Eds), Springer Verlag, Berlin 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/21\">",
"      Mobley HL. Defining Helicobacter pylori as a pathogen: strain heterogeneity and virulence. Am J Med 1996; 100:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/22\">",
"      Blaser MJ. Role of vacA and the cagA locus of Helicobacter pylori in human disease. Aliment Pharmacol Ther 1996; 10 Suppl 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/23\">",
"      Figura N. Helicobacter pylori exotoxins and gastroduodenal diseases associated with cytotoxic strain infection. Aliment Pharmacol Ther 1996; 10 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/24\">",
"      Tombola F, Morbiato L, Del Giudice G, et al. The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia. J Clin Invest 2001; 108:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/25\">",
"      Fujikawa A, Shirasaka D, Yamamoto S, et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet 2003; 33:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/26\">",
"      Letley DP, Rhead JL, Twells RJ, et al. Determinants of non-toxicity in the gastric pathogen Helicobacter pylori. J Biol Chem 2003; 278:26734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/27\">",
"      Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A 1993; 90:5791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/28\">",
"      Jenks PJ, Kusters JG. Pathogenesis and virulence factors of Helicobacter pylori. Curr Opin Gastroenterol 2000; 16:s11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/29\">",
"      Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/30\">",
"      Naumann M. Pathogenicity island-dependent effects of Helicobacter pylori on intracellular signal transduction in epithelial cells. Int J Med Microbiol 2005; 295:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/31\">",
"      Tegtmeyer N, Wessler S, Backert S. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J 2011; 278:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/32\">",
"      Spechler SJ, Fischbach L, Feldman M. Clinical aspects of genetic variability in Helicobacter pylori. JAMA 2000; 283:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/33\">",
"      Tummuru MK, Sharma SA, Blaser MJ. Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol Microbiol 1995; 18:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/34\">",
"      Covacci A, Rappuoli R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med 2000; 191:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/35\">",
"      Yamaoka Y, Kita M, Kodama T, et al. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996; 110:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/36\">",
"      Yamaoka Y, Kita M, Kodama T, et al. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 1997; 41:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/37\">",
"      Weel JF, van der Hulst RW, Gerrits Y, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1996; 173:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/38\">",
"      Day AS, Jones NL, Lynett JT, et al. cagE is a virulence factor associated with Helicobacter pylori-induced duodenal ulceration in children. J Infect Dis 2000; 181:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/39\">",
"      Fallone CA, Barkun AN, G&ouml;ttke MU, et al. Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. Am J Gastroenterol 2000; 95:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/40\">",
"      Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/41\">",
"      Basso D, Zambon CF, Letley DP, et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008; 135:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/42\">",
"      van Doorn LJ, Figueiredo C, Sanna R, et al. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori. Gastroenterology 1998; 115:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/43\">",
"      Atherton JC, Cao P, Peek RM Jr, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270:17771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/44\">",
"      Atherton JC, Peek RM Jr, Tham KT, et al. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 1997; 112:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/45\">",
"      Peek RM Jr, Thompson SA, Donahue JP, et al. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome. Proc Assoc Am Physicians 1998; 110:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/46\">",
"      Nogueira C, Figueiredo C, Carneiro F, et al. Helicobacter pylori genotypes may determine gastric histopathology. Am J Pathol 2001; 158:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/47\">",
"      Gerhard M, Lehn N, Neumayer N, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A 1999; 96:12778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/48\">",
"      Yamaoka Y, Kikuchi S, el-Zimaity HM, et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/49\">",
"      Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection. Helicobacter 2010; 15 Suppl 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/50\">",
"      Crabtree JE. Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment Pharmacol Ther 1996; 10 Suppl 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/51\">",
"      Ernst PB, Jin Y, Reyes VE, Crowe SE. The role of the local immune response in the pathogenesis of peptic ulcer formation. Scand J Gastroenterol Suppl 1994; 205:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/52\">",
"      Portal-Celhay C, Perez-Perez GI. Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. Clin Sci (Lond) 2006; 110:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/53\">",
"      Robinson K, Kenefeck R, Pidgeon EL, et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 2008; 57:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/54\">",
"      Di Tommaso A, Xiang Z, Bugnoli M, et al. Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies. Infect Immun 1995; 63:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/55\">",
"      Fan XG, Chua A, Fan XJ, Keeling PW. Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. J Clin Pathol 1995; 48:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/56\">",
"      Crowe SE, Alvarez L, Dytoc M, et al. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 1995; 108:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/57\">",
"      Das S, Suarez G, Beswick EJ, et al. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol 2006; 176:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/58\">",
"      Elliott SN, Ernst PB, Kelly CP. The year in Helicobacter pylori 2001: Molecular inflammation. Curr Opin Gastroenterol Suppl 2001; 17:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/59\">",
"      Wang J, Brooks EG, Bamford KB, et al. Negative selection of T cells by Helicobacter pylori as a model for bacterial strain selection by immune evasion. J Immunol 2001; 167:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/60\">",
"      Elizalde JI, G&oacute;mez J, Pan&eacute;s J, et al. Platelet activation In mice and human Helicobacter pylori infection. J Clin Invest 1997; 100:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/61\">",
"      Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003; 124:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/62\">",
"      Handin RI. A hitchhiker's guide to the galaxy--an H. pylori travel guide. Gastroenterology 2003; 124:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/63\">",
"      El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/64\">",
"      El-Omar EM. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut 2001; 48:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/65\">",
"      Persson C, Canedo P, Machado JC, et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 2011; 173:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/66\">",
"      Crabtree JE, Covacci A, Farmery SM, et al. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. J Clin Pathol 1995; 48:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/67\">",
"      Keates S, Hitti YS, Upton M, Kelly CP. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology 1997; 113:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/68\">",
"      Moss SF, Legon S, Davies J, Calam J. Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut 1994; 35:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/69\">",
"      Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/70\">",
"      Mitchell HM, Hazell SL, Kolesnikow T, et al. Antigen recognition during progression from acute to chronic infection with a cagA-positive strain of Helicobacter pylori. Infect Immun 1996; 64:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/71\">",
"      Blecker U, Lanciers S, Hauser B, et al. The contribution of specific immunoglobulin M antibodies to the diagnosis of Helicobacter pylori infection in children. Eur J Gastroenterol Hepatol 1995; 7:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/72\">",
"      Kosunen TU. Antibody titres in Helicobacter pylori infection: implications in the follow-up of antimicrobial therapy. Ann Med 1995; 27:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/73\">",
"      Cover TL, Glupczynski Y, Lage AP, et al. Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 1995; 33:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/74\">",
"      Crabtree JE, Peichl P, Wyatt JI, et al. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 1993; 37:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/75\">",
"      Negrini R, Lisato L, Zanella I, et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology 1991; 101:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/76\">",
"      Negrini R, Savio A, Appelmelk BJ. Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter 1997; 2 Suppl 1:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/77\">",
"      Greiner A, Marx A, Heesemann J, et al. Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis. Lab Invest 1994; 70:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/78\">",
"      Sutton P, Lee A. Review article: Helicobacter pylori vaccines-the current status. Aliment Pharmacol Ther 2000; 14:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/79\">",
"      Blanchard TG, Czinn SJ. Immunology of Helicobacter pylori and prospects for vaccine. Gastroenterol Clin North Am 2000; 29:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/80\">",
"      Crabtree JE. Eradication of chronic Helicobacter pylori infection by therapeutic vaccination. Gut 1998; 43:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/81\">",
"      Lee A, Chen M. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun 1994; 62:3594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/82\">",
"      Marchetti M, Aric&ograve; B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995; 267:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/83\">",
"      Ferrero RL, Thiberge JM, Huerre M, Labigne A. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect Immun 1994; 62:4981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/84\">",
"      Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/85\">",
"      Radcliff FJ, Hazell SL, Kolesnikow T, et al. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun 1997; 65:4668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/86\">",
"      Kreiss C, Buclin T, Cosma M, et al. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet 1996; 347:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/87\">",
"      Malfertheiner P, Schultze V, Rosenkranz B, et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008; 135:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4809/abstract/88\">",
"      Corth&eacute;sy-Theulaz I, Porta N, Glauser M, et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995; 109:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4809=[""].join("\n");
var outline_f4_44_4809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACTERIAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bacterial attachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Release of enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bacterial strain differences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - CagA and VacA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23985291\">",
"      - Other virulence factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INFLAMMATORY RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Interleukin-8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Survival of H. pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTIBODY RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/15\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/15/30964\" title=\"picture 1A\">",
"      H pylori on crypt cells Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/20/42305\" title=\"picture 1B\">",
"      Adherence of Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=related_link\">",
"      Acute and chronic gastritis due to Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=related_link\">",
"      Bacteriology and epidemiology of Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=related_link\">",
"      Metaplastic (chronic) atrophic gastritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_44_4810="Porokeratosis";
var content_f4_44_4810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Porokeratosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4810/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4810/contributors\">",
"     Linda V Spencer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4810/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4810/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/44/4810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/44/4810/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/44/4810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2260502\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porokeratosis is a disorder of keratinization characterized by one or more atrophic macules or patches surrounded by a distinctive hyperkeratotic ridge-like border called a cornoid lamella (",
"    <a class=\"graphic graphic_picture graphicRef81011 graphicRef74020 graphicRef81874 graphicRef62258 graphicRef73545 \" href=\"UTD.htm?42/23/43386\">",
"     picture 1A-E",
"    </a>",
"    ). Multiple clinical variants of porokeratosis exist. Malignant transformation occurs in a minority of cases.",
"   </p>",
"   <p>",
"    Although clinical surveillance for malignant transformation is sufficient for the management of most patients with porokeratosis, patients who are concerned about the appearance of lesions or who have associated symptoms such as pruritus or pain may desire therapeutic intervention. Formal studies of the therapeutic options for porokeratosis are lacking, but various topical, excisional, destructive, and systemic therapies appear to be effective in some patients.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, diagnosis, and management of porokeratosis will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959602\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defining feature of porokeratosis is the clinical and histopathologic presence of a cornoid lamella, which typically manifests as a visible, thin keratotic rim at the periphery of a slightly atrophic skin lesion. The most commonly described variants of porokeratosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Disseminated superficial actinic porokeratosis",
"      </strong>",
"      (DSAP, OMIM #175900, %607728, %612293, and %612353)",
"     </li>",
"     <li>",
"      <strong>",
"       Disseminated superficial porokeratosis",
"      </strong>",
"      (DSP)",
"     </li>",
"     <li>",
"      <strong>",
"       Classic porokeratosis of Mibelli",
"      </strong>",
"      (OMIM %175800)",
"     </li>",
"     <li>",
"      <strong>",
"       Linear porokeratosis",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Porokeratosis plantaris palmaris et disseminata",
"      </strong>",
"      (porokeratosis palmaris et plantaris disseminata, PPPD, OMIM %175850)",
"     </li>",
"     <li>",
"      <strong>",
"       Punctate porokeratosis",
"      </strong>",
"      (sometimes considered a variant of PPPD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725539\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clonal proliferation of abnormal epidermal keratinocytes is believed to account for the clinical manifestations of porokeratosis. However, the pathway that leads to this process remains unknown. A variety of factors have been proposed as potential contributors, including genetic susceptibility, ultraviolet radiation, and immune status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959617\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited or sporadic genetic defects likely play an important role in porokeratosis. Studies in familial cases of disseminated superficial actinic porokeratosis (DSAP) support an autosomal dominant inheritance pattern with incomplete penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/1\">",
"     1",
"    </a>",
"    ]. Four potential chromosomal loci for DSAP have been identified, including DSAP1 (12q23.2-24.1), DSAP2 (15q25.1-26.1), DSAP3 (1p31.3-p31.1), and DSAP 4 (16q24.1-24.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In a Chinese study, mutations in the mevalonate kinase gene (",
"    <em>",
"     MVK",
"    </em>",
"    ), which is located at 12q24, were detected in some patients with DSAP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, familial cases of disseminated superficial porokeratosis (DSP) and porokeratosis plantaris palmaris et disseminata (PPPD) demonstrate autosomal dominant inheritance patterns. The loci linked to DSP and PPPD are on chromosome 18p11.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and chromosome 12q24.1-24.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/9\">",
"     9",
"    </a>",
"    ], respectively.",
"   </p>",
"   <p>",
"    Focal forms of porokeratosis, such as porokeratosis of Mibelli and linear porokeratosis may occur as a consequence of mosaicism. The occurrence of linear porokeratosis or porokeratosis of Mibelli in patients with DSAP has been attributed to this theory [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. In such cases, focal loss of heterozygosity via somatic mutations may result in the prominent, localized clinical manifestations that characterize linear porokeratosis and porokeratosis of Mibelli, while the relatively milder manifestations of DSAP appear in a generalized distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link&amp;anchor=H1497288#H1497288\">",
"     \"Basic principles of genetic disease\", section on 'Mosaicism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959624\">",
"    <span class=\"h2\">",
"     Ultraviolet radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to ultraviolet radiation may contribute to the development of porokeratosis. This assertion is supported by the observation that DSAP preferentially occurs on areas of exposed skin and in individuals with histories of extensive sun exposure. In addition, the administration of artificial ultraviolet light in experimental settings has resulted in the induction of DSAP lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these findings, a definitive role for ultraviolet radiation in porokeratosis remains uncertain. Improvement in DSAP after treatment with psoralen plus ultraviolet A (PUVA) therapy has been documented in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/13\">",
"     13",
"    </a>",
"    ]. The relative sparing of the face in DSAP also raises questions about the designation of ultraviolet radiation as a contributory factor. (See",
"    <a class=\"local\" href=\"#H725555\">",
"     'Disseminated superficial actinic porokeratosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959631\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-related immunosuppression or immunodeficiency in the setting of benign diseases or hematologic malignancy may increase risk for porokeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Estimates of the incidence of porokeratosis in immunosuppressed organ transplant recipients have ranged from less than 1 percent to as high as 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/16,19\">",
"     16,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Porokeratosis has occurred 4 months to 14 years after the initiation of systemic immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/19\">",
"     19",
"    </a>",
"    ]. DSP and porokeratosis of Mibelli are the most commonly associated variants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A contributory role for immunosuppression is supported by reports of remission of porokeratosis after cessation of immunosuppressive therapy in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The development of porokeratosis in sites of long-term potent topical corticosteroid use in another patient also suggests a role for immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959795\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional factors that have been associated with porokeratosis include radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/27\">",
"     27",
"    </a>",
"    ], liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], solid organ cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], and Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725547\">",
"    <span class=\"h1\">",
"     CLINICAL VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple clinical variants of porokeratosis have been described. Disseminated superficial actinic porokeratosis (DSAP) is generally accepted to be the most common variant, followed by porokeratosis of Mibelli. In one series of 31 patients in Singapore, DSAP, classical porokeratosis of Mibelli, linear porokeratosis, and porokeratosis plantaris palmaris et disseminata (PPPD) accounted for 42, 35, 13, and 10 percent of cases of porokeratosis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the unifying feature of the variants of porokeratosis is the cornoid lamella. Lesions typically begin as small keratotic papules that spread slowly and centrifugally [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725555\">",
"    <span class=\"h2\">",
"     Disseminated superficial actinic porokeratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated superficial actinic porokeratosis (DSAP) is the most common type of porokeratosis. DSAP occurs more frequently in women than men, with an estimated female to male ratio of approximately 1.8:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"     21",
"    </a>",
"    ]. The onset of disease typically occurs in the third or fourth decade of life, and patients frequently report a history of extensive exposure to natural or artificial ultraviolet radiation. Worsening of disease during the summer months may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DSAP is characterized by erythematous, skin-colored, or hyperpigmented well-defined macules that are typically less than 1 cm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef59742 graphicRef81874 graphicRef80248 \" href=\"UTD.htm?37/48/38665\">",
"     picture 1C, 1F-G",
"    </a>",
"    ). The cornoid lamella is often subtle, manifesting as a fine peripheral keratotic ridge. The distribution of lesions typically involves the extensor surfaces of the arms, legs, shoulders, or back, with sparing of the palms and soles. Facial lesions, a less common finding, occur in approximately 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of skin lesions in DSAP is variable. Only a few or several hundred lesions may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/13\">",
"     13",
"    </a>",
"    ]. The cosmetic appearance of DSAP is a common concern for patients with this disorder, and may be particularly bothersome for individuals who frequently wear skirts or shorts that expose the lower legs. Skin lesions are often asymptomatic, but pruritus or stinging sensations are estimated to occur in one-third to one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/13,21\">",
"     13,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H726119\">",
"    <span class=\"h2\">",
"     Disseminated superficial porokeratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated superficial porokeratosis (DSP) resembles DSAP, but lacks photodistribution, appearing in both sun-exposed and non-sun-exposed sites. Like DSAP, the palms and soles are typically spared.",
"   </p>",
"   <p>",
"    In contrast to DSAP, DSP often develops in childhood, most commonly between the ages of 5 and 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"     21",
"    </a>",
"    ]. As noted above, DSP also can occur in association with immunosuppression (see",
"    <a class=\"local\" href=\"#H959631\">",
"     'Immunosuppression'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In addition, DSP has been reported in a few patients with solid organ malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725563\">",
"    <span class=\"h2\">",
"     Classic porokeratosis of Mibelli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porokeratosis of Mibelli is the second most common type of porokeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/33\">",
"     33",
"    </a>",
"    ]. The disorder often begins in childhood and affects males approximately twice as frequently as females [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"     21",
"    </a>",
"    ]. Occasionally, lesions develop during adulthood, often in association with immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/15,17,19,38\">",
"     15,17,19,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Porokeratosis of Mibelli typically begins as a small, asymptomatic or slightly pruritic papule that slowly expands over the course of years. Faster growth may occur in the setting of immunosuppression. Well developed lesions are usually a few centimeters in diameter, and rarely, lesions grow to 10 to 20 cm in size. The term &ldquo;giant porokeratosis&rdquo; has been used to describe these exceptionally large lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic location for porokeratosis of Mibelli is on an extremity. However, lesions may occur in any site, including the palms, soles, genitalia, or mucous membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21,41,42\">",
"     21,41,42",
"    </a>",
"    ]. Patients usually present with a solitary lesion or a few asymmetrically distributed lesions. Occasionally widespread lesions occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/10,39,43\">",
"     10,39,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The site of the cornoid lamella is often prominent in lesions of porokeratosis of Mibelli. The lesion border is usually greater than 1 mm in height and a thin furrow is typically seen in the center of the ridge, causing an appearance that resembles the Great Wall of China (",
"    <a class=\"graphic graphic_picture graphicRef81011 graphicRef62674 graphicRef78667 \" href=\"UTD.htm?21/15/21754\">",
"     picture 1A, 1H-I",
"    </a>",
"    ). The center of the lesion may be slightly hypopigmented or hyperpigmented, minimally scaly, slightly atrophic, and hairless. Uncommonly, lesions manifest as confluent hyperkeratotic or verrucous thick plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725578\">",
"    <span class=\"h2\">",
"     Linear porokeratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear porokeratosis is a rare form of porokeratosis that may represent a segmental form of DSAP or DSP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. The skin lesions typically present during infancy or early childhood, but occasionally develop in adults. Females are slightly more likely to be affected than males [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of linear porokeratosis can be localized or generalized, and the configuration of lesions usually follows the lines of Blaschko (",
"    <a class=\"graphic graphic_figure graphicRef57219 \" href=\"UTD.htm?31/60/32710\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73545 graphicRef50928 \" href=\"UTD.htm?40/37/41560\">",
"     picture 1E, 1J",
"    </a>",
"    ). The localized presentation of linear porokeratosis presents as single or multiple plaques with hyperkeratotic peripheral rims on one extremity. As in porokeratosis of Mibelli, the hyperkeratotic border is often prominent, and a furrow is seen just inside of the hyperkeratotic ridge. In the generalized form of linear porokeratosis, lesions are found on more than one extremity or on the trunk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725586\">",
"    <span class=\"h2\">",
"     Porokeratosis plantaris palmaris et disseminata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porokeratosis plantaris palmaris et disseminata (PPPD) is a rare variant of porokeratosis that may develop at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/33\">",
"     33",
"    </a>",
"    ]. Lesions customarily first appear in adolescence or early adulthood. &nbsp;",
"   </p>",
"   <p>",
"    The initial manifestations of PPPD are multiple small, relatively uniform macules on the palms and soles that exhibit a slightly hyperpigmented and atrophic center and a minimally raised peripheral ridge [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. A serpiginous configuration may evolve over time.",
"   </p>",
"   <p>",
"    Patients with PPPD can also develop lesions on the trunk and extremities that resemble lesions of DSAP and DSP. Involvement of the oral mucosa may also occur as multiple small, depressed, opalescent rings with hyperemic borders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lesions of PPPD may be asymptomatic, pruritic, or tender to palpation. Porokeratoses on the feet may cause discomfort with walking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959736\">",
"    <span class=\"h2\">",
"     Punctate porokeratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Punctate porokeratosis is characterized by multiple, small, seed-like, keratotic lesions on the palms and soles that have histopathologic findings consistent with a cornoid lamella. Some authors consider punctate porokeratosis to be a forme fruste of PPPD, rather than a separate entity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190517\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porokeratosis ptychotropica is an additional variant of porokeratosis. This type of porokeratosis presents with inflammatory keratotic plaques on the buttocks and multiple histopathologic foci of cornoid lamellae [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Lesions of porokeratosis ptychotropica are often mistaken for psoriasis (",
"    <a class=\"graphic graphic_picture graphicRef53110 graphicRef61803 \" href=\"UTD.htm?40/35/41528\">",
"     picture 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other subtypes of porokeratosis that have been described in the literature include follicular porokeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], eruptive pruritic papular porokeratosis in the setting of DSP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/55-57\">",
"     55-57",
"    </a>",
"    ], giant porokeratosis (see",
"    <a class=\"local\" href=\"#H725563\">",
"     'Classic porokeratosis of Mibelli'",
"    </a>",
"    above), and porokeratosis in a syndrome with craniosynostosis and anal anomalies (CAP syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725594\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of porokeratosis often can be made based solely on clinical examination. The clinical appearance of an atrophic macule or patch with a well-defined, raised, hyperkeratotic ridge suggests this disorder. Marker ink or iodine can be used to highlight the appearance of the cornoid lamella in subtle cases. Self-tanning lotions containing dihydroxyacetone also highlight the cornoid lamella.",
"   </p>",
"   <p>",
"    Skin biopsies usually are not necessary. Biopsies are typically performed when the appearance of the lesion is not classic or when there is concern for malignant transformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725602\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A shave biopsy deep enough to incorporate the mid dermis is adequate for diagnosis, provided that it includes the edge of the lesion (site of the cornoid lamella). Small lesions may be removed entirely by shave excision. A punch biopsy of the lesion edge may also be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H5#H5\">",
"     \"Skin biopsy techniques\", section on 'Biopsy techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classic histopathologic feature of porokeratosis is the cornoid lamella, a thin column of tightly packed parakeratotic cells within a keratin-filled epidermal invagination (",
"    <a class=\"graphic graphic_picture graphicRef61211 graphicRef67831 graphicRef66289 \" href=\"UTD.htm?38/44/39626\">",
"     picture 3A-C",
"    </a>",
"    ). The apex of the column angles away from the center of the lesion, and the base of the column demonstrates interruption of the epidermal granular layer and dyskeratotic keratinocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/19\">",
"     19",
"    </a>",
"    ]. A moderate lymphocytic inflammatory infiltrate is typically present in the papillary dermis. In addition, dermal amyloid deposits are occasionally seen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/50,59,60\">",
"     50,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the vast majority of biopsy specimens that demonstrate a cornoid lamella are derived from true porokeratoses, the finding is not exclusive to these lesions. Rarely, cornoid lamellae may be seen in other disorders, such as actinic keratoses, seborrheic keratoses, viral warts, and basal cell or squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725610\">",
"    <span class=\"h2\">",
"     Dermoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermoscopy is a noninvasive test that can be useful for diagnosis if the clinician has access to the equipment and is trained in its use. On dermoscopic examination, the coronoid lamella appears as a thin white rim lined by brown pigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. The atrophic center of a lesion often demonstrates a white area with red dots, globules, and lines that represent capillary vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H726924\">",
"    <span class=\"h2\">",
"     Other laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;No serologic tests are useful for the diagnosis of porokeratosis. The possibility of associated immunosuppression or internal malignancy (especially hematologic malignancy) should be considered in adults who present with new onset porokeratosis of Mibelli or PPPD, or sudden exacerbations of a longstanding porokeratotic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959986\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of a cornoid lamella on clinical exam in a lesion suspicious for porokeratosis is usually sufficient for diagnosis. However, when patients present with less classic findings, other disorders that share other features with porokeratosis must be considered. In such cases, a biopsy of the lesion is often helpful for distinguishing between porokeratosis and other disorders.",
"   </p>",
"   <p>",
"    Lesions of disseminated superficial actinic porokeratosis (DSAP) or disseminated superficial porokeratosis (DSP) clinically may resemble:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple actinic keratoses (",
"      <a class=\"graphic graphic_picture graphicRef53177 \" href=\"UTD.htm?26/19/26932\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Macular seborrheic keratoses",
"     </li>",
"     <li>",
"      Inflammatory skin disorders such as guttate psoriasis, pityriasis rosea, nummular dermatitis, tinea corporis, and lichen planus (",
"      <a class=\"graphic graphic_picture graphicRef55141 graphicRef57568 graphicRef55949 \" href=\"UTD.htm?22/20/22858\">",
"       picture 5A-C",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lesions of porokeratosis of Mibelli clinically may resemble:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cutaneous squamous cell carcinoma in situ (",
"      <a class=\"graphic graphic_picture graphicRef82358 \" href=\"UTD.htm?38/34/39464\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tinea corporis (",
"      <a class=\"graphic graphic_picture graphicRef55949 \" href=\"UTD.htm?20/24/20865\">",
"       picture 5C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Granuloma annulare (",
"      <a class=\"graphic graphic_picture graphicRef73823 \" href=\"UTD.htm?2/4/2115\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lichen simplex chronicus",
"     </li>",
"     <li>",
"      Circumscribed palmar or plantar hypokeratosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lesions of linear porokeratosis clinically may resemble:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Linear warts",
"     </li>",
"     <li>",
"      Lichen striatus",
"     </li>",
"     <li>",
"      Linear verrucous epidermal nevus",
"     </li>",
"     <li>",
"      Linear Darier disease",
"     </li>",
"     <li>",
"      Porokeratotic adnexal osteal nevus (a proposed term that incorporates porokeratotic eccrine ostial and dermal duct nevus [PEODDN] and porokeratotic eccrine and hair follicle nevus [PEHFN])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to porokeratosis plantaris palmaris et disseminata (PPPD) and punctate porokeratosis, other disorders may present with discrete keratotic lesions on the palms and soles. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arsenical keratoses (",
"      <a class=\"graphic graphic_picture graphicRef57673 \" href=\"UTD.htm?6/24/6528\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Palmoplantar keratodermas",
"     </li>",
"     <li>",
"      Palmar pits in basal cell nevus syndrome (",
"      <a class=\"graphic graphic_picture graphicRef72687 \" href=\"UTD.htm?25/24/25989\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959924\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND MALIGNANT TRANSFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/67\">",
"     67",
"    </a>",
"    ]Without treatment, lesions of porokeratosis usually persist indefinitely. Spontaneous regression is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498955\">",
"    <span class=\"h2\">",
"     Malignant transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant transformation has occurred in patients with all major variants of porokeratosis with the exception of punctate porokeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/67\">",
"     67",
"    </a>",
"    ]. It is estimated to occur in 7.5 to 11 percent of patients, with an average period to cancer onset of 36 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"     21",
"    </a>",
"    ]. Squamous cell carcinoma is the most common associated malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/68\">",
"     68",
"    </a>",
"    ]. Basal cell carcinoma may also occur.",
"   </p>",
"   <p>",
"    Linear porokeratosis and giant porokeratosis (a manifestation of porokeratosis of Mibelli) are the variants most susceptible to malignant transformation, while this occurrence in disseminated superficial actinic porokeratosis (DSAP) is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/67,69,70\">",
"     67,69,70",
"    </a>",
"    ]. One review of 281 patients with porokeratosis found risks for malignant transformation in patients with linear porokeratosis, porokeratosis plantaris palmaris et disseminata, porokeratosis of Mibelli of any size, and DSAP of 19, 10, 8, and 3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/67\">",
"     67",
"    </a>",
"    ]. Large lesion size, location on the extremities, and long lesion duration are additional factors that have been identified as risk factors for malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21,67,71,72\">",
"     21,67,71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to cutaneous squamous cell carcinoma unrelated to porokeratosis, the vast majority of squamous cell carcinomas that develop in lesions of porokeratosis are successfully treated with local therapy. However, several cases of metastatic squamous cell carcinoma arising in the setting of porokeratosis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/70,73-76\">",
"     70,73-76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498948\">",
"    <span class=\"h3\">",
"     Prevention and surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although removal of lesions via surgical or destructive methods is an option for the prevention of malignant transformation in lesions of porokeratosis, the need to do so is questionable. Factors such as the estimated risk for malignancy for specific lesion types and the risk for significant cosmetic or functional defects following removal must be considered. The removal of the lesions with the greatest risk for malignancy (linear porokeratosis or large porokeratosis of Mibelli) often would result in an unfavorable amount of scarring. Moreover, the large number of lesions and low risk for malignancy in individual lesions of DSAP or DSP suggest that the benefit of lesion removal for the prevention of malignancy in these variants is likely to be minimal.",
"   </p>",
"   <p>",
"    The ability to clinically follow lesions of porokeratosis for signs or symptoms of malignancy and the high likelihood of successful treatment of malignancy once it develops support clinical surveillance as an acceptable method of management, and thus, most patients with porokeratosis are followed clinically. We suggest the following approach to managing these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patient education &ndash;",
"      </strong>",
"      All patients should be educated about warning signs for malignancy. Patients should be instructed to return for follow-up if changes occur in a previously stable lesion, such as the development of induration, ulceration, nodularity, bleeding, crusting, or rapid growth. Similarly, patients should return for reevaluation if new symptoms develop in lesions (eg, prickling or tingling sensations or pain). &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Sun protection &ndash;",
"      </strong>",
"      The implementation of sun-protective practices is recommended to reduce actinic damage as well as to avoid sun-induced impairment in cutaneous immune surveillance, both of which may increase risk for cutaneous malignancy (see",
"      <a class=\"local\" href=\"#H959933\">",
"       'General measures'",
"      </a>",
"      below). &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Routine follow-up &ndash;",
"      </strong>",
"      Patients should be followed annually to monitor for signs and symptoms of malignancy, to screen for changes in health status that might suggest an underlying systemic disorder, and to reinforce sun protection education. Any lesion that exhibits clinical features concerning for malignancy (eg, induration, ulceration, bleeding, crusting, or rapid growth) should be excised or biopsied for histopathological examination. Although malignant transformation in DSAP and DSP are rare, the frequent presence of additional risk factors for cutaneous malignancy (eg, history of extensive sun exposure or immunosuppression) makes close clinical follow-up of these patients worthwhile.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the decision is made to excise or destroy a lesion for prophylactic purposes, doing so in an urgent manner is not necessary, as the period between lesion development and malignancy often spans decades (see",
"    <a class=\"local\" href=\"#H498955\">",
"     'Malignant transformation'",
"    </a>",
"    above). After removal, clinical follow-up still should be performed yearly to evaluate these patients for the development of new or recurrent lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H748631\">",
"    <span class=\"h3\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although systemic immunosuppression has not been proven to increase the risk for malignant transformation in lesions of porokeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/19\">",
"     19",
"    </a>",
"    ], immunosuppression is a known risk factor for cutaneous malignancy. Thus, skin examinations are often performed more than once yearly for skin cancer surveillance in this population regardless of the presence or absence of porokeratosis. The exact frequency of follow-up is dependent upon the individual&rsquo;s risk factors for skin cancer and his or her personal history of actinic keratoses or malignant lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link&amp;anchor=H2294684#H2294684\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Follow-up and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authors have advocated routine surgical removal or destruction of porokeratosis lesions in immunosuppressed patients due to concern for an increased risk for metastasis in these patients once squamous cell carcinoma has developed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/19,70\">",
"     19,70",
"    </a>",
"    ]. However, as noted above, complete removal of lesions at greatest risk for malignancy often is impractical; thus, we follow most of these patients clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H748770\">",
"    <span class=\"h3\">",
"     Role of pharmacologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic retinoids are occasionally used for the management of patients with severe porokeratosis. Based upon studies in squamous cell carcinoma, the risk for malignant transformation to squamous cell carcinoma may be reduced during active treatment with systemic retinoids. However, this has not been directly studied in porokeratosis, and the long-term impact of retinoid therapy on malignant transformation of these lesions is unknown. The effect of topical therapies on the risk for malignancy also is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H32#H32\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Oral retinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725618\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of therapeutic interventions have been used in the management of porokeratosis. Pruritus, pain, and cosmetic concerns are common indications for treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553762\">",
"    <span class=\"h2\">",
"     Approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the treatment of porokeratosis include topical pharmacologic therapy, destructive therapies, surgical excision, and systemic retinoids. Since no randomized trials have evaluated therapies for porokeratosis and the available data are insufficient for definitive recommendations on management, the approach to therapy is based primarily upon factors such as lesion size, lesion location, aesthetic considerations, treatment availability, and patient preference. If the intent of treatment is removal for malignancy prophylaxis, more definitive procedures such as surgical excision or lesion destruction are typically recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/19,70\">",
"     19,70",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H498955\">",
"     'Malignant transformation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our general approach to benign-appearing lesions that are being treated for symptomatic or cosmetic reasons is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who desire quick therapy for a few small lesions and who would not be disturbed by residual changes in skin pigmentation or scarring, we typically treat with cryotherapy, electrodesiccation and curettage, or surgical excision. (See",
"      <a class=\"local\" href=\"#H553341\">",
"       'Physical interventions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients with multiple or large lesions, cryotherapy and electrodesiccation are often impractical, and we consider treatment with topical pharmacologic therapy. Several case reports have documented lesion resolution after several weeks of therapy with topical 5-fluorouracil (5-FU) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/28,77-80\">",
"       28,77-80",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/81-85\">",
"       81-85",
"      </a>",
"      ] with no or minimal scarring, and we consider these agents appropriate first-line therapies. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the intense inflammatory response that typically accompanies treatment with topical 5-FU or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    limits the amount of skin that can be treated at one time. If treatment of a large area is required, treatment with a topical retinoid such as tretinoin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    may be effective. Topical vitamin D analogs may also help to improve lesions in patients with disseminated superficial actinic porokeratosis (DSAP) or disseminated superficial porokeratosis (DSP). However, a disadvantage of topical retinoids and topical vitamin D agents is that several months or more of treatment may be required. (See",
"    <a class=\"local\" href=\"#H553782\">",
"     'Topical therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The response to treatment with topical agents is often unpredictable, and clinicians must remain cognizant that lesions that initially respond well to any treatment can recur.",
"   </p>",
"   <p>",
"    Additional options for the treatment of porokeratosis include topical keratolytics (eg, salicylic acid), laser therapy, dermabrasion, and photodynamic therapy. Systemic retinoids are generally restricted to severe cases due to the possibility of systemic adverse effects and the high likelihood for lesion recurrence after the discontinuation of treatment. (See",
"    <a class=\"local\" href=\"#H553341\">",
"     'Physical interventions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H553623\">",
"     'Systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959933\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the possibility for malignant transformation in porokeratosis, we strongly encourage patients to engage in protection from ultraviolet radiation, a known risk factor for squamous cell and basal cell carcinoma. We recommend sun protective clothing, shelter from the sun, and routine daily use of sunscreen on areas of skin that cannot be protected physically. Of note, strict use of sun protection may increase the risk for vitamin D deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link&amp;anchor=H7#H7\">",
"     \"Sunburn\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liberal use of emollients may be useful in patients with porokeratosis, as they may reduce the rough, dry quality of lesions. As noted above, patients should also be followed closely for signs of malignancy. (See",
"    <a class=\"local\" href=\"#H498948\">",
"     'Prevention and surveillance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553782\">",
"    <span class=\"h2\">",
"     Topical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the efficacy of topical therapies for porokeratosis is limited to case reports and small case series. The response to topical treatments is unpredictable, and the optimal treatment regimens are unknown.",
"   </p>",
"   <p>",
"    Topical therapeutic options for porokeratosis are provided below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Topical 5-fluorouracil",
"      </strong>",
"      &ndash; Topical 5-FU has been effective for patients with DSAP, DSP, porokeratosis of Mibelli, and linear porokeratosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/28,77-80\">",
"       28,77-80",
"      </a>",
"      ]. We typically instruct patients to apply 5-FU 5% cream daily until an intense inflammatory response is attained (typically several weeks).",
"     </li>",
"     <li>",
"      <strong>",
"       Topical",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      &ndash; Topical imiquimod has improved lesions in patients with DSAP, porokeratosis of Mibelli, linear porokeratosis, and porokeratosis plantaris palmaris et disseminata (PPPD) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/81-89\">",
"       81-89",
"      </a>",
"      ]. A reasonable initial course of therapy for imiquimod is application three to five times per week for a period of four to six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/81-83\">",
"       81-83",
"      </a>",
"      ]. Longer or shorter periods of treatment may be needed depending on the treatment response and the occurrence of adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]. Similar to topical 5-FU, an intense local inflammatory response is expected during treatment with imiquimod.",
"     </li>",
"     <li>",
"      <strong>",
"       Topical retinoids",
"      </strong>",
"      &ndash; Tretinoin 0.05% cream and 0.1% gel have been beneficial for the treatment of linear porokeratosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/90-92\">",
"       90-92",
"      </a>",
"      ]. An advantage of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       topical tretinoin",
"      </a>",
"      over topical 5-FU and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      is the induction of relatively less inflammation and irritation during the course of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/90\">",
"       90",
"      </a>",
"      ]. However, based upon reports in patients with linear porokeratosis, daily application for 10 to 16 weeks may be required [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/91,92\">",
"       91,92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Topical",
"      </strong>",
"      <strong>",
"       vitamin D",
"      </strong>",
"      <strong>",
"       analogs",
"      </strong>",
"      &ndash; Topical vitamin D analogs, such as calcipotriol and tacalcitol are also less irritating than 5-FU and imiquimod. These agents have only been reported to be effective in DSAP, and several months or more of treatment may be required for improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/93-96\">",
"       93-96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Combination therapy &ndash;",
"      </strong>",
"      In our experience, pre-treatment of affected skin with a topical retinoid such as tretinoin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"       tazarotene",
"      </a>",
"      for two to three weeks prior to the use of topical 5-FU or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      seems to improve drug penetration and the response to therapy. The relative efficacy of this regimen to treatment with topical 5-FU or imiquimod alone has not been formally studied in porokeratosis. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other topical agents may also be effective. The application of keratolytic agents such as salicylic acid may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/97\">",
"     97",
"    </a>",
"    ]. Successful treatment with salicylic acid in combination with 5-FU or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    also has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/89,98\">",
"     89,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    3% gel, an agent used in the treatment of actinic keratoses, is unclear. In a series of eight patients with DSAP, only one patient had partial improvement after six months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/99\">",
"     99",
"    </a>",
"    ], but the results of a separate small case series suggested that the drug may have an effect on reducing disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical corticosteroids have also been used in the treatment of porokeratosis. We prefer to avoid these agents due to the theoretical potential for an increased risk for malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553341\">",
"    <span class=\"h2\">",
"     Physical interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porokeratoses can be removed or improved with procedures such as cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/101-103\">",
"     101-103",
"    </a>",
"    ], electrodesiccation and curettage, surgical excision, and dermabrasion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Light-based therapies may also be effective. Carbon dioxide lasers have successfully treated porokeratosis of Mibelli and linear porokeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/106-109\">",
"     106-109",
"    </a>",
"    ], and improvement in DSAP or DSP has been reported after treatment with a fractional laser [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/110\">",
"     110",
"    </a>",
"    ], Q-switched ruby laser [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/111,112\">",
"     111,112",
"    </a>",
"    ], or a frequency-doubled Nd:YAG laser [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/113\">",
"     113",
"    </a>",
"    ]. Pulsed dye laser therapy was effective in one patient with linear porokeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/114\">",
"     114",
"    </a>",
"    ]. Case reports of photodynamic therapy in DSAP and linear porokeratosis have yielded variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/115-119\">",
"     115-119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553623\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral retinoids are infrequently used for the treatment of severe cases of porokeratosis. The initial studies of systemic retinoid therapy were performed using etretinate, a drug that was removed from the commercial market. Subsequent patients have been managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Retinoids have been reported to be effective in patients with DSAP, linear porokeratosis, porokeratosis of Mibelli, and PPPD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/120-126\">",
"     120-126",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    given for five to seven months at doses of 30 mg per day or 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day has been associated with improvement in patients with generalized linear lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/122,123\">",
"     122,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although systemic retinoid therapy can reduce lesion severity, the degree of improvement is variable and recurrence after the discontinuation of systemic retinoids is likely. Of note, exacerbation of DSP during etretinate therapy was reported in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/44/4810/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191710\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Porokeratosis is a disorder of keratinization that is distinguished from other skin disorders by the presence of a characteristic ridge-like keratotic border called a cornoid lamella. A variety of types of porokeratosis have been described, all of which share this distinctive feature. (See",
"      <a class=\"local\" href=\"#H959602\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of porokeratosis is poorly understood. Factors such as genetic susceptibility, exposure to ultraviolet radiation, and immunosuppression may contribute to lesion development. (See",
"      <a class=\"local\" href=\"#H725539\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated superficial actinic porokeratosis (DSAP) is the most common form of porokeratosis. Patients are typically adults with a history of extensive sun exposure. Few or many small, porokeratotic macules are usually present on the extensor extremities. (See",
"      <a class=\"local\" href=\"#H725555\">",
"       'Disseminated superficial actinic porokeratosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Porokeratosis of Mibelli is the second most common type of porokeratosis. Lesions most commonly begin in childhood, but may occur in adults, particularly in the setting of immunosuppression. An annular plaque a few centimeters in diameter with a prominent keratotic ridge is the typical clinical finding. (See",
"      <a class=\"local\" href=\"#H725563\">",
"       'Classic porokeratosis of Mibelli'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical examination is usually sufficient for the diagnosis of porokeratosis. Skin biopsies may be useful in the setting of atypical lesions or lesions that are suspicious for malignant transformation. Biopsy of the periphery of the lesion characteristically demonstrates a narrow column of parakeratosis. (See",
"      <a class=\"local\" href=\"#H725594\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignant transformation is estimated to occur in 7.5 to 11 percent of patients with porokeratosis. Malignancy is most likely to occur in lesions of linear porokeratosis or giant porokeratosis (a form of porokeratosis of Mibelli). Complete removal or destruction of lesions to prevent malignant transformation often is impractical. Thus, patients with porokeratosis should be followed closely for signs of malignant disease. (See",
"      <a class=\"local\" href=\"#H959924\">",
"       'Prognosis and malignant transformation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is not required for most patients with porokeratosis, but may be desired by patients with symptomatic or cosmetically distressing lesions. (See",
"      <a class=\"local\" href=\"#H725618\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with only a few small lesions who desire rapid treatment for symptomatic or cosmetic purposes and who are willing to accept treatment-related pigment changes or scarring, we suggest treatment with cryotherapy, electrodesiccation and curettage, or surgical excision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      For patients with large or multiple lesions or who are concerned about the possibility of scarring with the interventions above, we suggest treatment with topical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical 5-FU or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      may be used for the treatment of localized areas.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       Topical tretinoin",
"      </a>",
"      and topical vitamin D analogs are less irritating therapeutic options, but may require long courses of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional choices for lesion destruction include dermabrasion, laser therapy, and photodynamic therapy. (See",
"      <a class=\"local\" href=\"#H553341\">",
"       'Physical interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with systemic retinoids is usually reserved for severe cases. Relapse is likely after treatment cessation. (See",
"      <a class=\"local\" href=\"#H553623\">",
"       'Systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/1\">",
"      Murase J, Gilliam AC. Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: Update on the genetics and clinical expression of porokeratosis. J Am Acad Dermatol 2010; 63:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/2\">",
"      Xia JH, Yang YF, Deng H, et al. Identification of a locus for disseminated superficial actinic porokeratosis at chromosome 12q23.2-24.1. J Invest Dermatol 2000; 114:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/3\">",
"      Xia K, Deng H, Xia JH, et al. A novel locus (DSAP2) for disseminated superficial actinic porokeratosis maps to chromosome 15q25.1-26.1. Br J Dermatol 2002; 147:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/4\">",
"      Liu P, Zhang S, Yao Q, et al. Identification of a genetic locus for autosomal dominant disseminated superficial actinic porokeratosis on chromosome 1p31.3-p31.1. Hum Genet 2008; 123:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/5\">",
"      Luan J, Niu Z, Zhang J, et al. A novel locus for disseminated superficial actinic porokeratosis maps to chromosome 16q24.1-24.3. Hum Genet 2011; 129:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/6\">",
"      Zhang SQ, Jiang T, Li M, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet 2012; 44:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/7\">",
"      Wei S, Yang S, Lin D, et al. A novel locus for disseminated superficial porokeratosis maps to chromosome 18p11.3. J Invest Dermatol 2004; 123:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/8\">",
"      Wei S, Zhang TD, Zhou Y, et al. Fine mapping of the disseminated superficial porokeratosis locus to a 2.7 Mb region at 18p11.3. Clin Exp Dermatol 2010; 35:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/9\">",
"      Wei SC, Yang S, Li M, et al. Identification of a locus for porokeratosis palmaris et plantaris disseminata to a 6.9-cM region at chromosome 12q24.1-24.2. Br J Dermatol 2003; 149:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/10\">",
"      Happle R. Mibelli revisited: a case of type 2 segmental porokeratosis from 1893. J Am Acad Dermatol 2010; 62:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/11\">",
"      Chernosky ME, Freeman RG. Disseminated superficial actinic porokeratosis (DSAP). Arch Dermatol 1967; 96:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/12\">",
"      Neumann RA, Knobler RM, Jurecka W, Gebhart W. Disseminated superficial actinic porokeratosis: experimental induction and exacerbation of skin lesions. J Am Acad Dermatol 1989; 21:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/13\">",
"      Schwarz T, Seiser A, Gschnait F. Disseminated superficial \"actinic\" porokeratosis. J Am Acad Dermatol 1984; 11:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/14\">",
"      Raychaudhuri SP, Smoller BR. Porokeratosis in immunosuppressed and nonimmunosuppressed patients. Int J Dermatol 1992; 31:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/15\">",
"      Rodr&iacute;guez EA, Jakubowicz S, Chinchilla DA, et al. Porokeratosis of Mibelli and HIV-infection. Int J Dermatol 1996; 35:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/16\">",
"      Herranz P, Pizarro A, De Lucas R, et al. High incidence of porokeratosis in renal transplant recipients. Br J Dermatol 1997; 136:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/17\">",
"      Alexis AF, Busam K, Myskowski PL. Porokeratosis of Mibelli following bone marrow transplantation. Int J Dermatol 2006; 45:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/18\">",
"      Komorowski RA, Clowry LJ. Porokeratosis of mibelli in transplant recipients. Am J Clin Pathol 1989; 91:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/19\">",
"      Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol 1998; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/20\">",
"      Rothman IL, Wirth PB, Klaus MV. Porokeratosis of Mibelli following heart transplant. Int J Dermatol 1992; 31:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/21\">",
"      Sertznig P, von Felbert V, Megahed M. Porokeratosis: present concepts. J Eur Acad Dermatol Venereol 2012; 26:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/22\">",
"      Gilead L, Guberman D, Zlotogorski A, et al. Immunosuppression-induced porokeratosis of Mibelli: Complete regression of lesions upon cessation of immunosuppressive therapy. J Eur Acad Dermatol Venereol 1995; 5:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/23\">",
"      Tsambaos D, Spiliopoulos T. Disseminated superficial porokeratosis: complete remission subsequent to discontinuation of immunosuppression. J Am Acad Dermatol 1993; 28:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/24\">",
"      Yazkan F, Turk BG, Dereli T, Kazandi AC. Porokeratosis of Mibelli induced by topical corticosteroid. J Cutan Pathol 2006; 33:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/25\">",
"      James AJ, Clarke LE, Elenitsas R, Katz K. Segmental porokeratosis after radiation therapy for follicular lymphoma. J Am Acad Dermatol 2008; 58:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/26\">",
"      Roman&iacute; J, Pujol RM, Casanova JM, de Moragas JM. Disseminated superficial porokeratosis developing after electron-beam total skin irradiation for mycosis fungoides. Clin Exp Dermatol 1996; 21:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/27\">",
"      Nova MP, Goldberg LJ, Mattison T, Halperin A. Porokeratosis arising in a burn scar. J Am Acad Dermatol 1991; 25:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/28\">",
"      Dippel E, Haas N, Czarnetzki BM. Porokeratosis of Mibelli associated with active chronic hepatitis and vitiligo. Acta Derm Venereol 1994; 74:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/29\">",
"      Hunt SJ, Sharra WG, Abell E. Linear and punctate porokeratosis associated with end-stage liver disease. J Am Acad Dermatol 1991; 25:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/30\">",
"      Cannav&oacute; SP, Borgia F, Adamo B, Guarneri B. Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? J Am Acad Dermatol 2008; 58:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/31\">",
"      Kono T, Kobayashi H, Ishii M, et al. Synchronous development of disseminated superficial porokeratosis and hepatitis C virus-related hepatocellular carcinoma. J Am Acad Dermatol 2000; 43:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/32\">",
"      Morton CA, Shuttleworth D, Douglas WS. Porokeratosis and Crohn's disease. J Am Acad Dermatol 1995; 32:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/33\">",
"      Leow YH, Soon YH, Tham SN. A report of 31 cases of porokeratosis at the National Skin Centre. Ann Acad Med Singapore 1996; 25:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/34\">",
"      Sawyer R, Picou KA. Facial presentation of disseminated superficial actinic porokeratosis. Ear Nose Throat J 1989; 68:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/35\">",
"      Bencini PL, Tarantino A, Grimalt R, et al. Porokeratosis and immunosuppression. Br J Dermatol 1995; 132:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/36\">",
"      Chun SI, Lee JS, Kim NS, Park KD. Disseminated epidermolytic acanthoma with disseminated superficial porokeratosis and verruca vulgaris in an immunosuppressed patient. J Dermatol 1995; 22:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/37\">",
"      Rio B, Magana C, Le Tourneau A, et al. Disseminated superficial porokeratosis after autologous bone marrow transplantation. Bone Marrow Transplant 1997; 19:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/38\">",
"      Knoell KA, Patterson JW, Wilson BB. Sudden onset of disseminated porokeratosis of Mibelli in a renal transplant patient. J Am Acad Dermatol 1999; 41:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/39\">",
"      Bozda�� KE, Bi&ccedil;ak&ccedil;i H, Ermete M. Giant porokeratosis. Int J Dermatol 2004; 43:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/40\">",
"      Raychaudhury T, Valsamma DP. Giant porokeratosis. Indian J Dermatol Venereol Leprol 2011; 77:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/41\">",
"      Robinson JB, Im DD, Jockle G, Rosenshein NB. Vulvar porokeratosis: case report and review of the literature. Int J Gynecol Pathol 1999; 18:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/42\">",
"      Neri I, Marzaduri S, Passarini B, Patrizi A. Genital porokeratosis of Mibelli. Genitourin Med 1995; 71:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/43\">",
"      Koley S, Sarkar J, Choudhary S, et al. Different morphological variants of hypertrophic porokeratosis and disseminated lesions of porokeratosis of Mibelli: a rare co-existence. Indian J Dermatol Venereol Leprol 2011; 77:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/44\">",
"      Thomas C, Ogboli MI, Carr RA, Charles-Holmes R. Hypertrophic perianal porokeratosis in association with superficial actinic porokeratosis of the leg. Clin Exp Dermatol 2003; 28:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/45\">",
"      Lestringant GG, Berge T. Porokeratosis punctata palmaris et plantaris. A new entity? Arch Dermatol 1989; 125:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/46\">",
"      Sakas EL, Gentry RH. Porokeratosis punctata palmaris et plantaris (punctate porokeratosis). Case report and literature review. J Am Acad Dermatol 1985; 13:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/47\">",
"      Marschalk&oacute; M, Somlai B. Porokeratosis plantaris, palmaris, et disseminata. Arch Dermatol 1986; 122:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/48\">",
"      Patrizi A, Passarini B, Minghetti G, Masina M. Porokeratosis palmaris et plantaris disseminata: an unusual clinical presentation. J Am Acad Dermatol 1989; 21:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/49\">",
"      Barnes L, Mimouni F, Lucky AW. Solitary nodule on the arm of an infant. Infantile myofibromatosis (IM). Arch Dermatol 1986; 122:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/50\">",
"      Tallon B, Blumental G, Bhawan J. Porokeratosis ptychotropica: a lesser-known variant. Clin Exp Dermatol 2009; 34:e895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/51\">",
"      McGuigan K, Shurman D, Campanelli C, Lee JB. Porokeratosis ptychotropica: a clinically distinct variant of porokeratosis. J Am Acad Dermatol 2009; 60:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/52\">",
"      Lee Y, Choi EH. Exclusive facial porokeratosis: histopathologically showing follicular cornoid lamellae. J Dermatol 2011; 38:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/53\">",
"      Rocha-Sousa VL, Costa JB, de Aquino Paulo-Filho T, et al. Follicular porokeratosis on the face. Am J Dermatopathol 2011; 33:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/54\">",
"      Wang NS, Gruson LM, Kamino H. Facial follicular porokeratosis: a case report. Am J Dermatopathol 2010; 32:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/55\">",
"      Kanekura T, Yoshii N. Eruptive pruritic papular porokeratosis: a pruritic variant of porokeratosis. J Dermatol 2006; 33:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/56\">",
"      Kanzaki T, Miwa N, Kobayashi T, Ogawa S. Eruptive pruritic papular porokeratosis. J Dermatol 1992; 19:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/57\">",
"      Stork J, Kodetov&aacute; D. Disseminated superficial porokeratosis: an eruptive pruritic papular variant. Dermatology 1997; 195:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/58\">",
"      Flanagan N, Boyadjiev SA, Harper J, et al. Familial craniosynostosis, anal anomalies, and porokeratosis: CAP syndrome. J Med Genet 1998; 35:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/59\">",
"      Uenishi T, Teramura K, Kitamura M, et al. Hyperkeratotic variant of porokeratosis Mibelli with dermal amyloid deposits. J Dermatol 2010; 37:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/60\">",
"      Carlesimo M, Rossi A, Fidanza L, et al. Disseminated Superficial Porokeratosis with Dermal Amyloid Deposits. Case Rep Dermatol 2009; 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/61\">",
"      Wade TR, Ackerman AB. Cornoid lamellation. A histologic reaction pattern. Am J Dermatopathol 1980; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/62\">",
"      Zaballos P, Puig S, Malvehy J. Dermoscopy of disseminated superficial actinic porokeratosis. Arch Dermatol 2004; 140:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/63\">",
"      Panasiti V, Rossi M, Curzio M, et al. Disseminated superficial actinic porokeratosis diagnosed by dermoscopy. Int J Dermatol 2008; 47:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/64\">",
"      Uhara H, Kamijo F, Okuyama R, Saida T. Open pores with plugs in porokeratosis clearly visualized with the dermoscopic furrow ink test: report of 3 cases. Arch Dermatol 2011; 147:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/65\">",
"      Oiso N, Kawada A. Dermoscopic features in disseminated superficial actinic porokeratosis. Eur J Dermatol 2011; 21:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/66\">",
"      Pizzichetta MA, Canzonieri V, Massone C, Soyer HP. Clinical and dermoscopic features of porokeratosis of Mibelli. Arch Dermatol 2009; 145:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/67\">",
"      Sasson M, Krain AD. Porokeratosis and cutaneous malignancy. A review. Dermatol Surg 1996; 22:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/68\">",
"      Maubec E, Duvillard P, Margulis A, et al. Common skin cancers in porokeratosis. Br J Dermatol 2005; 152:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/69\">",
"      Goerttler EA, Jung EG. Porokeratosis [correction of Parakeratosis] Mibelli and skin carcinoma: a critical review. Humangenetik 1975; 26:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/70\">",
"      Silver SG, Crawford RI. Fatal squamous cell carcinoma arising from transplant-associated porokeratosis. J Am Acad Dermatol 2003; 49:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/71\">",
"      Otsuka F, Umebayashi Y, Watanabe S, et al. Porokeratosis large skin lesions are susceptible to skin cancer development: histological and cytological explanation for the susceptibility. J Cancer Res Clin Oncol 1993; 119:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/72\">",
"      Lin JH, Hsu MM, Sheu HM, Lee JY. Coexistence of three variants of porokeratosis with multiple squamous cell carcinomas arising from lesions of giant hyperkeratotic porokeratosis. J Eur Acad Dermatol Venereol 2006; 20:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/73\">",
"      Rongioletti F, Rebora A. Disseminated porokeratosis with fatal metastatic squamous cell carcinoma: an additional case of \"malignant disseminated porokeratosis\". Am J Dermatopathol 2002; 24:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/74\">",
"      Sawai T, Hayakawa H, Danno K, et al. Squamous cell carcinoma arising from giant porokeratosis: a case with extensive metastasis and hypercalcemia. J Am Acad Dermatol 1996; 34:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/75\">",
"      Lozinski AZ, Fisher BK, Walter JB, Fitzpatrick PJ. Metastatic squamous cell carcinoma in linear porokeratosis of Mibelli. J Am Acad Dermatol 1987; 16:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/76\">",
"      Anzai S, Takeo N, Yamaguchi T, et al. Squamous cell carcinoma in a renal transplant recipient with linear porokeratosis. J Dermatol 1999; 26:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/77\">",
"      Shelley WB, Shelley ED. Disseminated superficial porokeratosis: rapid therapeutic response to 5-fluorouracil. Cutis 1983; 32:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/78\">",
"      Gon&ccedil;alves JC. Fluorouracil ointment treatment of porokeratosis of Mibelli. Arch Dermatol 1973; 108:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/79\">",
"      McDonald SG, Peterka ES. Porokeratosis (Mibelli): treatment with topical 5-fluorouracil. J Am Acad Dermatol 1983; 8:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/80\">",
"      Balato N, Di Nardo G, Boccia L, Nappa P. [Linear Mibelli's porokeratosis. Treatment with topical 5-fluorouracil]. G Ital Dermatol Venereol 1986; 121:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/81\">",
"      Harrison S, Sinclair R. Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream. Australas J Dermatol 2003; 44:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/82\">",
"      Montes-De-Oca-S&aacute;nchez G, Tirado-S&aacute;nchez A, Garc&iacute;a-Ram&iacute;rez V. Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. J Dermatolog Treat 2006; 17:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/83\">",
"      Arun B, Pearson J, Chalmers R. Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream. Clin Exp Dermatol 2011; 36:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/84\">",
"      Jain S. Successful treatment of porokeratosis of Mibelli with imiquimod 5% cream. Clin Exp Dermatol 2006; 31:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/85\">",
"      Ahn SJ, Lee HJ, Chang SE, et al. Case of linear porokeratosis: successful treatment with topical 5% imiquimod cream. J Dermatol 2007; 34:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/86\">",
"      Agarwal S, Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol 2002; 146:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/87\">",
"      Jensen JM, Egberts F, Proksch E, Hauschild A. Disseminated porokeratosis palmaris and plantaris treated with imiquimod cream to prevent malignancy. Acta Derm Venereol 2005; 85:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/88\">",
"      Esser AC, Pittelkow MR, Randle HW. Human papillomavirus isolated from transplant-associated porokeratoses of mibelli responsive to topical 5% imiquimod cream. Dermatol Surg 2006; 32:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/89\">",
"      Erbagci Z, Tuncel AA, Erbagci I. Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases. J Drugs Dermatol 2006; 5:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/90\">",
"      Grover C, Goel A, Nanda S, et al. A case of extensive linear porokeratosis with evaluation of topical tretinoin versus 5-flourouracil as treatment modalities. J Dermatol 2005; 32:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/91\">",
"      Dervis E, Demirkesen C. Generalized linear porokeratosis. Int J Dermatol 2006; 45:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/92\">",
"      Agrawal SK, Gandhi V, Madan V, Bhattacharya SN. Topical tretinoin in Indian male with zosteriform porokeratosis. Int J Dermatol 2003; 42:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/93\">",
"      B&ouml;hm M, Luger TA, Bonsmann G. Disseminated superficial actinic porokeratosis: treatment with topical tacalcitol. J Am Acad Dermatol 1999; 40:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/94\">",
"      Abe M, Yokoyama Y, Ishikawa O. Successful treatment of disseminated superficial actinic porokeratosis with tacalcitol lotion. J Dermatol 2010; 37:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/95\">",
"      Harrison PV, Stollery N. Disseminated superficial actinic porokeratosis responding to calcipotriol. Clin Exp Dermatol 1994; 19:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/96\">",
"      Niimi Y, Kawana S. Type 2 segmental manifestation of disseminated superficial actinic porokeratosis in a 7-year-old girl. Eur J Dermatol 2009; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/97\">",
"      Jih MH. Porokeratosis plantaris, palmaris, et disseminata. Dermatol Online J 2003; 9:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/98\">",
"      Danby W. Treatment of porokeratosis with fluorouracil and salicylic acid under occlusion. Dermatol Online J 2003; 9:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/99\">",
"      Vlachou C, Kanelleas AI, Martin-Clavijo A, Berth-Jones J. Treatment of disseminated superficial actinic porokeratosis with topical diclofenac gel: a case series. J Eur Acad Dermatol Venereol 2008; 22:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/100\">",
"      Marks S, Varma R, Cantrell W, et al. Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol 2009; 23:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/101\">",
"      Bhushan M, Craven NM, Beck MH, Chalmers RJ. Linear porokeratosis of mibelli: successful treatment with cryotherapy. Br J Dermatol 1999; 141:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/102\">",
"      Chowdhury MM, Inaloz HS, Holt PJ. A scaly macule on the bridge of the nose of a 15-year-old boy. Pediatr Dermatol 2000; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/103\">",
"      Carranza DC, Haley JC, Chiu M. Facial porokeratosis. Skinmed 2008; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/104\">",
"      Cohen PR, Held JL, Katz BE. Linear porokeratosis: successful treatment with diamond fraise dermabrasion. J Am Acad Dermatol 1990; 23:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/105\">",
"      Spencer JM, Katz BE. Successful treatment of porokeratosis of Mibelli with diamond fraise dermabrasion. Arch Dermatol 1992; 128:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/106\">",
"      Barnett JH. Linear porokeratosis: treatment with the carbon dioxide laser. J Am Acad Dermatol 1986; 14:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/107\">",
"      Rabbin PE, Baldwin HE. Treatment of porokeratosis of Mibelli with CO2 laser vaporization versus surgical excision with split-thickness skin graft. A comparison. J Dermatol Surg Oncol 1993; 19:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/108\">",
"      Hunziker T, Bayard W. Carbon dioxide laser in the treatment of porokeratosis. J Am Acad Dermatol 1987; 16:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/109\">",
"      McCullough TL, Lesher JL Jr. Porokeratosis of Mibelli: rapid recurrence of a large lesion after carbon dioxide laser treatment. Pediatr Dermatol 1994; 11:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/110\">",
"      Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Fractional photothermolysis: a novel treatment for disseminated superficial actinic porokeratosis. Arch Dermatol 2007; 143:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/111\">",
"      Itoh M, Nakagawa H. Successful treatment of disseminated superficial actinic porokeratosis with Q-switched ruby laser. J Dermatol 2007; 34:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/112\">",
"      Lolis MS, Marmur ES. Treatment of disseminated superficial actinic porokeratosis (DSAP) with the Q-switched ruby laser. J Cosmet Laser Ther 2008; 10:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/113\">",
"      Liu HT. Treatment of lichen amyloidosis (LA) and disseminated superficial porokeratosis (DSP) with frequency-doubled Q-switched Nd:YAG laser. Dermatol Surg 2000; 26:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/114\">",
"      Alster TS, Nanni CA. Successful treatment of porokeratosis with 585 nm pulsed dye laser irradiation. Cutis 1999; 63:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/115\">",
"      Nayeemuddin FA, Wong M, Yell J, Rhodes LE. Topical photodynamic therapy in disseminated superficial actinic porokeratosis. Clin Exp Dermatol 2002; 27:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/116\">",
"      Fern&aacute;ndez-Guarino M, Harto A, P&eacute;rez-Garcia B, et al. Photodynamic therapy in disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol 2009; 23:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/117\">",
"      Cavicchini S, Tourlaki A. Successful treatment of disseminated superficial actinic porokeratosis with methyl aminolevulinate-photodynamic therapy. J Dermatolog Treat 2006; 17:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/118\">",
"      Garc&iacute;a-Navarro X, Garc&eacute;s JR, Baselga E, Alomar A. Linear porokeratosis: excellent response to photodynamic therapy. Arch Dermatol 2009; 145:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/119\">",
"      Levitt J, Emer JJ, Emanuel PO. Treatment of porokeratosis of mibelli with combined use of photodynamic therapy and Fluorouracil cream. Arch Dermatol 2010; 146:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/120\">",
"      Hartman R, Mandal R, Sanchez M, Stein JA. Porokeratosis plantaris, palmaris, et disseminata. Dermatol Online J 2010; 16:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/121\">",
"      McCallister RE, Estes SA, Yarbrough CL. Porokeratosis plantaris, palmaris, et disseminata. Report of a case and treatment with isotretinoin. J Am Acad Dermatol 1985; 13:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/122\">",
"      Hong JB, Hsiao CH, Chu CY. Systematized linear porokeratosis: a rare variant of diffuse porokeratosis with good response to systemic acitretin. J Am Acad Dermatol 2009; 60:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/123\">",
"      Garg T, Varghese B, Barara M, et al. Generalized linear porokeratosis: a rare entity with excellent response to acitretin. Dermatol Online J 2011; 17:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/124\">",
"      Goldman GD, Milstone LM. Generalized linear porokeratosis treated with etretinate. Arch Dermatol 1995; 131:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/125\">",
"      Hacham-Zadeh S, Holubar K. Etretinate in the treatment of disseminated porokeratosis of Mibelli. Int J Dermatol 1985; 24:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/126\">",
"      Gutierrez EL, Galarza C, Ramos W, et al. Facial porokeratosis: A series of six patients. Australas J Dermatol 2010; 51:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/44/4810/abstract/127\">",
"      Knobler RM, Neumann RA. Exacerbation of porokeratosis during etretinate therapy. Acta Derm Venereol 1990; 70:319.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13721 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-0D5B978519-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4810=[""].join("\n");
var outline_f4_44_4810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H191710\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2260502\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H959602\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H725539\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H959617\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H959624\">",
"      Ultraviolet radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H959631\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H959795\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H725547\">",
"      CLINICAL VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H725555\">",
"      Disseminated superficial actinic porokeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H726119\">",
"      Disseminated superficial porokeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H725563\">",
"      Classic porokeratosis of Mibelli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H725578\">",
"      Linear porokeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H725586\">",
"      Porokeratosis plantaris palmaris et disseminata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H959736\">",
"      Punctate porokeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190517\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H725594\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H725602\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H725610\">",
"      Dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H726924\">",
"      Other laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H959986\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H959924\">",
"      PROGNOSIS AND MALIGNANT TRANSFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H498955\">",
"      Malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H498948\">",
"      - Prevention and surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H748631\">",
"      - Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H748770\">",
"      - Role of pharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H725618\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553762\">",
"      Approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H959933\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553782\">",
"      Topical therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553341\">",
"      Physical interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553623\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191710\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13721|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/60/32710\" title=\"figure 1\">",
"      Lines of Blaschko",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13721|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/1/39957\" title=\"picture 1A\">",
"      Porokeratosis of Mibelli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/58/932\" title=\"picture 1B\">",
"      Porokeratosis on finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/36/44610\" title=\"picture 1C\">",
"      Disseminated superficial actinic porokeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/51/10038\" title=\"picture 1D\">",
"      Disseminated superficial actinic porokeratosis close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/0/5123\" title=\"picture 1E\">",
"      Linear porokeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/35/35377\" title=\"picture 1F\">",
"      Disseminated superficial actinic porokeratosis - legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/55/10098\" title=\"picture 1G\">",
"      Disseminated superficial actinic porokeratosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/59/21428\" title=\"picture 1H\">",
"      Porokeratosis multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/16/34048\" title=\"picture 1I\">",
"      Porokeratosis of Mibelli extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/17/43284\" title=\"picture 1J\">",
"      Linear porokeratosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/20/38211\" title=\"picture 2A\">",
"      Porokeratosis ptychotropica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/56/10116\" title=\"picture 2B\">",
"      Porokeratosis ptychotropica close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/61/2007\" title=\"picture 3A\">",
"      Porokeratosis histopathology 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/47/16116\" title=\"picture 3B\">",
"      Porokeratosis histopathology 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/0/15367\" title=\"picture 3C\">",
"      Porokeratosis histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/19/26932\" title=\"picture 4\">",
"      Actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/9/24725\" title=\"picture 5A\">",
"      Guttate psoriasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/20/22852\" title=\"picture 5B\">",
"      Pityriasis rosea trailing scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/24/20865\" title=\"picture 5C\">",
"      Tinea corporis - multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/34/39464\" title=\"picture 6\">",
"      Squamous cell carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/4/2115\" title=\"picture 7\">",
"      Localized granuloma annulare on hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/24/6528\" title=\"picture 8\">",
"      Arsenical skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/24/25989\" title=\"picture 9\">",
"      Palmar pits BCC nevus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=related_link\">",
"      Management of skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_44_4811="Quick sources of sugar for children PI";
var content_f4_44_4811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Quick sources of sugar to treat low blood sugar in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        3 or 4 glucose tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &frac12; cup of juice or regular soda (not sugar-free)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 tablespoons of raisins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 tablespoon of sugar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 tablespoon of honey, jelly, or syrup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hard candies, such as 6 lifesavers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These sources of sugar act quickly to treat low blood sugar levels. If your child has diabetes and uses insulin, you or your child should carry at least 1 of these items at all times. You should also leave quick sources of sugar at your child's school, and with babysitters and coaches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4811=[""].join("\n");
var outline_f4_44_4811=null;
var title_f4_44_4812="Rx options cardiogenic shock";
var content_f4_44_4812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for cardiogenic shock due to left ventricular dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       General measures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ventilation support to correct hypoxemia and, in part, acidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Optimize intravascular volume",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sodium bicarbonate only for severe metabolic acidosis (arterial pH less than 7.10 to 7.15)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aspirin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intravenous heparin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Possible glycoprotein IIb/IIIa inhibitor with NSTEMI",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Insertion of pulmonary artery catheter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Specific measures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Pharmacologic support",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sympathomimetic inotropes (eg, dopamine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Norepinephrine (for refractory hypotension)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Mechanical support",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       IABP, usually combined with percutaneous coronary intervention or coronary artery bypass graft surgery or possible thrombolytic therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Newer devices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Left ventricular or biventricular assist devices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Percutaneous cardiopulmonary bypass",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Reperfusion/revascularization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Primary percutaneous coronary intervention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Coronary artery bypass graft",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Thrombolytic therapy for patients not receiving PCI in a timely manner",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4812=[""].join("\n");
var outline_f4_44_4812=null;
var title_f4_44_4813="Common long-term and late effects of breast cancer treatment";
var content_f4_44_4813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common long-term and late effects of breast cancer treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management options",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Surgical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cosmetic effects",
"       </td>",
"       <td>",
"        Plastic surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Functional disability of arm or chest wall, pain",
"       </td>",
"       <td>",
"        Physical therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scarring/adhesions",
"       </td>",
"       <td>",
"        Plastic surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphedema",
"       </td>",
"       <td>",
"        Physical therapy, avoid trauma to involved arm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Second malignancies",
"       </td>",
"       <td>",
"        Image masses arising near radiation field",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        Check TSH if symptoms of hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumonitis, pulmonary fibrosis",
"       </td>",
"       <td>",
"        Symptomatic management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac damage",
"       </td>",
"       <td>",
"        Lifestyle risk-reduction (diet, exercise, tobacco avoidance)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphedema",
"       </td>",
"       <td>",
"        As above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Systemic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Second malignancies (myelodysplasia and leukemia)",
"       </td>",
"       <td>",
"        Check CBC if symptoms of leukemia arise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ototoxicity (eg, cisplatin)",
"       </td>",
"       <td>",
"        Symptomatic management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiomyopathy (eg, anthracyclines)",
"       </td>",
"       <td>",
"        Symptomatic management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal toxicity (eg, cisplatin)",
"       </td>",
"       <td>",
"        Symptomatic management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Premature menopause and infertility (eg, alkylating agents)",
"       </td>",
"       <td>",
"        Referral to infertility specialist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Menopausal symptoms",
"       </td>",
"       <td>",
"        Gabapentin, SNRI (eg, venlafaxine), SSRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sexual dysfunction",
"       </td>",
"       <td>",
"        Counseling, lubricants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osteoporosis (eg, hormonal therapy, chemotherapy)",
"       </td>",
"       <td>",
"        Calcium, vitamin D, exercise, bisphosphonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuropathy (eg, taxanes and platinums)",
"       </td>",
"       <td>",
"        Symptomatic management (eg, antidepressants, antiepileptics for painful neuropathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cognitive dysfunction",
"       </td>",
"       <td>",
"        Cognitive therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weight gain",
"       </td>",
"       <td>",
"        Exercise and diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fatigue",
"       </td>",
"       <td>",
"        Exercise, rule out other causes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; SNRI: serotonin-norepinephrine reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TSH: thyroid stimulating hormone.",
"    </div>",
"    <div class=\"reference\">",
"     Source: Hayes DF. Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med 2007; 356:2505.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4813=[""].join("\n");
var outline_f4_44_4813=null;
var title_f4_44_4814="Diff dx preeclampsia";
var content_f4_44_4814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64296%7EOBGYN%2F65674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64296%7EOBGYN%2F65674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of various signs and symptoms among imitators of preeclampsia-eclampsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Signs and symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        HELLP syndrome, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        AFLP, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        TTP, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        HUS, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Exacerbation of SLE, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        20-75",
"       </td>",
"       <td>",
"        80-90",
"       </td>",
"       <td>",
"        80 with APA, nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinuria",
"       </td>",
"       <td>",
"        90-95",
"       </td>",
"       <td>",
"        30-50",
"       </td>",
"       <td>",
"        With hematuria",
"       </td>",
"       <td>",
"        80-90",
"       </td>",
"       <td>",
"        100 with nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        25-32",
"       </td>",
"       <td>",
"        20-50",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Common during flare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        40-90",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        50-80",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Only with APA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"       <td>",
"        60-80",
"       </td>",
"       <td>",
"        35-50",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Only with APA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system",
"       </td>",
"       <td>",
"        40-60",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"       <td>",
"        60-70",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        50 with APA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HELLP: hemolysis, elevated liver enzymes, low platelets; AFLP: acute fatty liver of pregnancy; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; SLE: systemic lupus erythematosus; APA: antiphospholipid antibodies with or without catastrophic antiphospholipid syndrome; NR: values not reported; Common: reported as the most common presentation.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol 2007; 109:956. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency and severity of laboratory findings among imitators of preeclampsia-eclampsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Laboratory findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        HELLP syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        AFLP",
"       </td>",
"       <td class=\"subtitle1\">",
"        TTP",
"       </td>",
"       <td class=\"subtitle1\">",
"        HUS",
"       </td>",
"       <td class=\"subtitle1\">",
"        Exacerbation of SLE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia (less than 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        More than 20,000",
"       </td>",
"       <td>",
"        More than 50,000",
"       </td>",
"       <td>",
"        20,000 or less",
"       </td>",
"       <td>",
"        More than 20,000",
"       </td>",
"       <td>",
"        More than 20,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemolysis (percent)",
"       </td>",
"       <td>",
"        50-100",
"       </td>",
"       <td>",
"        15-20",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        14-23 with APA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia (percent)",
"       </td>",
"       <td>",
"        Less than 50",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        14-23 with APA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DIC (percent)",
"       </td>",
"       <td>",
"        Less than 20",
"       </td>",
"       <td>",
"        50-100",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia (percent)",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        50-100",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VW factor multimers (percent)",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        80-90",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        Less than 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADAMTS13 less than 5 percent (percent)",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        33-100",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired renal function (percent)",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        90-100",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        40-80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LDH (IU/L)",
"       </td>",
"       <td>",
"        600 or more",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        More than 1000",
"       </td>",
"       <td>",
"        More than 1000",
"       </td>",
"       <td>",
"        With APA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated ammonia (percent)",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated bilirubin (percent)",
"       </td>",
"       <td>",
"        50-60",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Less than 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated transaminases (percent)",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        Usually mild*",
"       </td>",
"       <td>",
"        Usually mild*",
"       </td>",
"       <td>",
"        With APA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HELLP: hemolysis, elevated liver enzymes, low platelets; AFLP: acute fatty liver of pregnancy; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; SLE: systemic lupus erythematosus; APA: antiphospholipid antibodies with or without catastrophic antiphospholipid syndrome; DIC; disseminated intravascular coagulopathy: VW: von Willebrand; ADAMTS: von Willebrand factor-cleaving metalloprotease; LDH: lactic dehydrogenase; NR: values are not available.",
"     <br>",
"      * Levels less than 100 IU/L.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol 2007; 109:956. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4814=[""].join("\n");
var outline_f4_44_4814=null;
var title_f4_44_4815="Oral Rx sexual dysfunction";
var content_f4_44_4815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80719%7EPC%2F53269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80719%7EPC%2F53269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral treatments for male sexual dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism and clinical use",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects and precautions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug interactions*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual dosing",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Phosphodiesterase type 5 (PDE5) inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sildenafil",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits enzyme phosphodiesterase 5, allowing cyclic GMP to accumulate within penis.",
"        </p>",
"        <p>",
"         Effective for as-needed treatment of organic, psychogenic, or mixed type ED.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Headaches, dyspepsia, vasodilation, diarrhea, rhinitis, epistaxis, and blue tinge to vision.",
"        </p>",
"        <p>",
"         Contraindicated if using nitrates due to risk of severe hypotension and syncope.",
"        </p>",
"        <p>",
"         Co-administration with alpha-1 blockers may cause symptomatic hypotension. If co-administered, we suggest first stabilizing patient on alpha-1 blocker dose prior to starting PDE5 inhibitor at a reduced dose. Tamsulosin and silodosin may be better tolerated than other alpha-1 blockers.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sildenafil is metabolized by CYP3A4.",
"         <br/>",
"         Strong inhibitors of CYP3A4 (eg, HIV protease inhibitors",
"         <sup>",
"          &Delta;",
"         </sup>",
"         , systemic-azole antifungals) elevate sildenafil concentrations.",
"        </p>",
"        <p>",
"         Inducers of CYP3A4 may reduce sildenafil concentrations.",
"        </p>",
"        <p>",
"         A list of CYP3A4 inhibitors and inducers is provided in a separate table.",
"        </p>",
"        <p>",
"         We suggest avoidance of large amounts of grapefruit and its&nbsp;juice (a CYP3A4 inhibitor).",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Taken one hour before sex and effective up to four hours",
"        </p>",
"        <p>",
"         Stimulation needed for erection",
"        </p>",
"        <p>",
"         Dose: 50 to 100 mg on empty stomach",
"        </p>",
"        <p>",
"         A reduced dose of 25 mg is recommended&nbsp;if &nbsp;coadministered with a strong inhibitor of CYP3A4 or an&nbsp;alpha-1 blocker",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vardenafil",
"       </td>",
"       <td>",
"        Same as sildenafil",
"       </td>",
"       <td>",
"        Similar efficacy, adverse effects, and precautions to sildenafil, but no visual side effects.",
"       </td>",
"       <td>",
"        Same as sildenafil",
"       </td>",
"       <td>",
"        <p>",
"         Similar onset and duration of action as sildenafil",
"        </p>",
"        <p>",
"         Dose: 10 to 20 mg on empty stomach about 60 minutes before sexual activity",
"        </p>",
"        <p>",
"         Orally disintegrating tablet (ODT): 10 mg on empty stomach (no titration)",
"        </p>",
"        <p>",
"         A reduced dose of 2.5 or 5 mg is recommended if coadministered with a strong inhibitor of CYP3A4 or an alpha-1 blocker, respectively. (See Lexicomp for individual drug monograph for detail).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tadalafil",
"       </td>",
"       <td>",
"        <p>",
"         Similar onset of action as sildenafil",
"        </p>",
"        <p>",
"         Duration of action up to 36 hours",
"        </p>",
"        <p>",
"         Effective for as-needed",
"         <strong>",
"          or",
"         </strong>",
"         daily treatment of organic, psychogenic, or mixed type ED",
"        </p>",
"       </td>",
"       <td>",
"        Similar efficacy, side effects, and precautions to sildenafil, but no visual side effects.",
"       </td>",
"       <td>",
"        Same as sildenafil",
"       </td>",
"       <td>",
"        <p>",
"         As-needed treatment: 10 to 20 mg about 60 minutes before sexual activity",
"        </p>",
"        <p>",
"         10 mg not more than once every 72 hours is recommended&nbsp;if coadministered with&nbsp;a strong inhibitor of CYP3A4;",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Daily treatment: 2.5 to 5 mg once daily",
"        </p>",
"        <p>",
"         2.5 mg once daily is recommended&nbsp;if coadministered with&nbsp;a strong inhibitor of CYP3A4 or alpha-1 blocker",
"        </p>",
"        <p>",
"         NOTE: Absorption is not altered by food",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion (sustained release and extended release)",
"       </td>",
"       <td>",
"        <p>",
"         Increases noradrenergic and dopaminergic activity; mild stimulant effect.",
"        </p>",
"        <p>",
"         Mitigates selective serotonin reuptake inhibitor (SSRI) associated decreased libido and ED. Refer to UpToDate topic on sexual dysfunction associated with SSRIs.",
"        </p>",
"        <p>",
"         Treats depression; antidepressant effect may not be evident until after several weeks of therapy.",
"        </p>",
"       </td>",
"       <td>",
"        Dry mouth, headache, insomnia, anxiety, agitation.",
"       </td>",
"       <td>",
"        <p>",
"         Bupropion is metabolized by&nbsp;CYP2B6 and UDP-GT glucuronidation;&nbsp;it inhibits CYP2D6.",
"        </p>",
"        Does not interact with PDE5 inhibitors",
"       </td>",
"       <td>",
"        <p>",
"         150 to 400 mg per day in divided doses (sustained release)",
"        </p>",
"        <p>",
"         150 to 450 mg once per day (extended release)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxetine",
"       </td>",
"       <td>",
"        <p>",
"         Increases serotoninergic activity.",
"        </p>",
"        <p>",
"         May benefit men suffering from premature ejaculation when used as intermittent or daily treatment.",
"        </p>",
"        <p>",
"         Treats depression; antidepressant effect may not be evident until after several weeks of daily therapy.",
"        </p>",
"        <p>",
"         Other SSRIs, including sertraline, are likely to produce similar effects.",
"        </p>",
"       </td>",
"       <td>",
"        Dry mouth, headache, mild sedation, decreased libido, and erectile function.",
"       </td>",
"       <td>",
"        <p>",
"         Paroxetine is&nbsp;metabolized by&nbsp;and&nbsp;inhibits CYP2D6.",
"        </p>",
"        <p>",
"         SSRI-associated sexual dysfunction&nbsp;can negate benefit of PDE5 inhibitor.",
"        </p>",
"       </td>",
"       <td>",
"        10 to 20 mg three to four hours before planned sexual activity or once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trazodone",
"       </td>",
"       <td>",
"        <p>",
"         Seortonin modulation and alpha-1 antagonism.",
"        </p>",
"        <p>",
"         Used for psychogenic ED.",
"        </p>",
"        <p>",
"         May benefit men suffering from premature ejaculation.",
"        </p>",
"        <p>",
"         May not be effective for treatment of depression in dose range shown.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Dizziness, lethargy, sedation.",
"        </p>",
"        <p>",
"         Dose related orthostatic hypotension, gastrointestinal toxicity, QTc prolongation, and weight gain.",
"        </p>",
"        <p>",
"         May cause priapsim.",
"        </p>",
"       </td>",
"       <td>",
"        Trazodone is&nbsp;metabolized by&nbsp;CYP1A2, 2D6, and 3A4; it is an inducer of P-gp.",
"       </td>",
"       <td>",
"        25 to 100 mg before sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Other therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Yohimbine",
"        </p>",
"        <p>",
"         In US available as an ingredient in some non-prescription dietary supplements (yohimbe",
"         <sup>",
"          &loz;",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Blocks presynaptic alpha-2 receptors.",
"        </p>",
"        <p>",
"         Stimulates mid-brain, increases libido.",
"        </p>",
"        <p>",
"         Might increase local blood flow, decreases outflow.",
"        </p>",
"        <p>",
"         Used for psychogenic ED.",
"        </p>",
"        <p>",
"         May have placebo effect.",
"        </p>",
"        <p>",
"         Alternative to testosterone for libido.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Dizziness, flushing, nausea, headache, anxiety, insomnia, elevated blood pressure, and increased heart rate; avoid with benign prostatic hyperplasia.",
"        </p>",
"        <p>",
"         Potency and purity of dietary supplements may not be assured.",
"        </p>",
"        <p>",
"         Long-term use is not recommended.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         May interact with antihypertensives, antidepressants, or stimulant medications.",
"        </p>",
"        <p>",
"         Data are lacking.",
"        </p>",
"       </td>",
"       <td>",
"        15 to 30 mg daily in two or three divided doses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CYP: cytochrome P450 drug metabolism; ED: erectile dysfunction; P-gp: P-glycoprotein efflux transporters; SSRI: selective serotonin reuptake inhibitor; UDP-GT: glucuronyltransferase drug metabolism (glucuronidation).",
"     <br>",
"      * A list of strong inhibitors and inducers of CYP 3A4 that can interact with PDE5 inhibitors is provided separately. Specific drug interactions and management suggestions may be determined by using Lexi-Interact, the drug interactions program included with UpToDate.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       One-half of the usual PDE5 dose shown above may have adequate effect and better tolerability in some patients. The co-administration of more than one PDE5 inhibitor or use more than once per day is not recommended. Recommendations for dose adjustment are based upon US licensed product information. Licensed recommendations may be different in other countries.",
"       <br>",
"        &Delta; Atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir. Interaction is of greater significance in ritonavir- or cobicistat-boosted regimens.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Additional information on yohimbe containing supplements is available from the US National Library of Medicine",
"         <a href=\"file://dietarysupplements.nlm.nih.gov/dietary/ingredDetail.jsp?contain=Yohimbe&amp;id=1298\" target=\"_blank\">",
"          Dietary Supplements Database",
"         </a>",
"         .",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suppositories, injections, and devices for treatment of male sexual dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Method of use and effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages and limitations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usage pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Suppository",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alprostadil intraurethral pellet",
"       </td>",
"       <td>",
"        Muse",
"       </td>",
"       <td>",
"        <p>",
"         Alprostadil (prostaglandin E1) in gel form delivered by applicator into meatus of penis.",
"        </p>",
"        Causes vasodilation by direct vascular smooth muscle relaxation allowing blood flow and entrapment in penis.",
"       </td>",
"       <td>",
"        <p>",
"         Less invasive than intracavernosal injections, but also less effective. Can be used twice daily.",
"        </p>",
"        Not recommended with pregnant partners.",
"       </td>",
"       <td>",
"        Inserted 5 to 10 minutes before sex. Effects last up to 1 hour.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Penile injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alprostadil",
"       </td>",
"       <td>",
"        <p>",
"         Caverject",
"        </p>",
"        Edex",
"       </td>",
"       <td>",
"        Prostaglandin E1 injected into base of penis. Causes smooth muscle relaxation in corpus cavernosae.",
"       </td>",
"       <td>",
"        <p>",
"         Effective in 50 to 85 percent of cases.",
"        </p>",
"        Disadvantages include dislike of penile self-injection, pain at injection site, requires reconstitution and sterile technique, not for use more than three times per week or more than once per 24 hours. Bleeding risk with anticoagulants. Priapism occurs uncommonly.",
"       </td>",
"       <td>",
"        Inject 10 to 20 minutes before sex. Erections may last over an hour.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasoactive intestinal peptide (VIP, aviptadil) and phentolamine",
"       </td>",
"       <td>",
"        Invicorp (not available in US)",
"       </td>",
"       <td>",
"        Causes vasodilation by direct vascular smooth muscle relaxation allowing blood flow and entrapment in penis.",
"       </td>",
"       <td>",
"        Possibly more effective than alprostadil. Causes less pain. Priapism rare.",
"       </td>",
"       <td>",
"        Inject 10 to 20 minutes before sex. Requires stimulation to have erection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vacuum pump",
"       </td>",
"       <td>",
"        Various",
"       </td>",
"       <td>",
"        Removes air from chamber over penis, creating a vacuum and drawing blood into penile cavernosae. Elastic tourniquet at base holds blood in penis.",
"       </td>",
"       <td>",
"        One-time expense. Safe if erection not maintained more than one hour. May not be acceptable to partner. Penis is hinged at base. May interfere with ejaculation. Can cause bruising of penis.",
"       </td>",
"       <td>",
"        Inflated just before sexual activity. Erection lasts until elastic ring removed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_44_4815=[""].join("\n");
var outline_f4_44_4815=null;
